

Fibrocell Science, Inc.  
Form 10-Q  
August 13, 2010

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 10-Q**

☒ **Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
For the quarterly period ended June 30, 2010**  
**OR**

☐ **Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Fibrocell Science, Inc.**

(Exact name of registrant as specified in its Charter.)

**Delaware**

(State or other jurisdiction  
of incorporation)

**001-31564**

(Commission File Number)

**87-0458888**

(I.R.S. Employer  
Identification No.)

**405 Eagleview Boulevard  
Exton, Pennsylvania 19341**

(Address of principal executive offices, including zip code)

**(484) 713-6000**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for any shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting  
company ☒

(Do not check if a smaller  
reporting company)

Indicate by check mark whether the registrant is shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☒ No ☐

As of August 11, 2010, issuer had 19,768,676 shares issued and outstanding of common stock, par value \$0.001.



## TABLE OF CONTENTS

	<b>Page</b>
<u>Part I. Financial Information</u>	
<u>Item 1. Financial Statements</u>	
<u>Consolidated Successor Balance Sheets (unaudited)</u> <u>June 30, 2010 and December 31, 2009</u>	1
<u>Consolidated Statements of Operations (unaudited)</u> <u>Three months ended June 30, 2010 (Successor Company), three months ended June 30, 2009</u> <u>(Predecessor Company)</u>	2
<u>Consolidated Statements of Operations (unaudited)</u> <u>Six months ended June 30, 2010 (Successor Company), cumulative period from inception</u> <u>(September 1, 2009) to June 30, 2010 (Successor Company), six months ended June 30, 2009</u> <u>(Predecessor Company) and cumulative period from inception (December 28, 1995) to August 31,</u> <u>2009 (Predecessor Company)</u>	3
<u>Consolidated Statements of Shareholders' Equity (Deficit) and Comprehensive Income (Loss)</u> <u>From inception (December 28, 1995) to August 31, 2009 (Predecessor Company) and from inception</u> <u>(September 1, 2009) to June 30, 2010 (Successor Company) (unaudited)</u>	4
<u>Consolidated Statements of Cash Flows (unaudited)</u> <u>Six months ended June 30, 2010 (Successor Company), cumulative period from inception</u> <u>(September 1, 2009) to June 30, 2010 (Successor Company), six months ended June 30, 2009</u> <u>(Predecessor Company) and cumulative period from inception (December 28, 1995) to August 31,</u> <u>2009 (Predecessor Company)</u>	16
<u>Notes to Unaudited Consolidated Financial Statements</u>	18
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	34
<u>Item 3. Quantitative and Qualitative Disclosures about Market Risk</u>	45
<u>Item 4. Controls and Procedures</u>	45
<u>Part II. Other Information</u>	
<u>Item 1A. Risk Factors</u>	46
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	46
<u>Item 6. Exhibits</u>	46
<u>Exhibit 31.1</u>	
<u>Exhibit 31.2</u>	

Exhibit 32.1

Exhibit 32.2

---

**Table of Contents****PART I FINANCIAL INFORMATION****ITEM 1. Financial statements.**

**Fibrocell Science, Inc.**  
**(A Development Stage Company)**  
**Consolidated Successor Balance Sheets**  
**(unaudited)**

	<b>June 30, 2010</b>	<b>December 31, 2009</b>
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 290,035	\$ 1,362,488
Accounts receivable, net	279,038	269,759
Inventory, net	233,778	226,032
Prepaid expenses and other current assets	329,850	525,024
Total current assets	1,132,701	2,383,303
Property and equipment, net of accumulated depreciation of \$3,140 and \$0, respectively	26,535	
Other assets	250	250
Intangible assets	6,340,656	6,340,656
Total assets	\$ 7,500,142	\$ 8,724,209
<b>Liabilities, Redeemable Preferred Stock, Shareholders' Deficit and Noncontrolling Interest</b>		
Current liabilities:		
Current debt	\$ 6,934	\$ 47,795
Accounts payable	780,157	245,023
Accrued expenses	1,614,487	544,260
Total current liabilities	2,401,578	837,078
Long-term debt	6,000,060	6,000,060
Deferred tax liability	2,500,000	2,500,000
Warrant liability	3,230,800	635,276
Other long-term liabilities	312,408	369,210
Total liabilities	14,444,846	10,341,624
Commitments and contingencies		
Redeemable preferred stock series A, \$1,000 par value; 9,000 shares authorized; 3,250 shares issued	2,414,059	2,511,070
Fibrocell Science, Inc. shareholders' deficit:		
Successor common stock, \$.001 par value; 250,000,000 shares authorized	19,769	14,692
Additional paid-in capital	1,715,944	508,347

Edgar Filing: Fibrocell Science, Inc. - Form 10-Q

Accumulated deficit during development stage	(11,509,339)	(5,049,999)
Total Fibrocell Science, Inc. shareholders' deficit	(9,773,626)	(4,526,960)
Noncontrolling interest	414,863	398,475
Total deficit and noncontrolling interest	(9,358,763)	(4,128,485)
Total liabilities, redeemable preferred stock, shareholders' deficit and noncontrolling interest	\$ 7,500,142	\$ 8,724,209

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents**

**Fibrocell Science, Inc.**  
**(A Development Stage Company)**  
**Consolidated Statements of Operations**  
**(unaudited)**

	<b>Successor For the three months ended June 30, 2010</b>	<b>Predecessor For the three months ended June 30, 2009</b>
Revenue		
Product sales	\$ 264,062	\$ 248,991
Total revenue	264,062	248,991
Cost of sales	175,916	107,929
Gross profit	88,146	141,062
Selling, general and administrative expenses	1,821,330	1,068,851
Research and development expenses	1,473,741	485,300
Operating loss	(3,206,925)	(1,413,089)
Other income (expense)		
Interest income		7
Reorganization items, net		(593,204)
Warrant income	1,712,430	
Interest expense	(203,268)	(969,200)
Loss from continuing operations	(1,697,763)	(2,975,486)
Loss from discontinued operations, net of tax	(12,502)	(142,780)
Net loss	(1,710,265)	(3,118,266)
Net loss attributable to noncontrolling interest	(1,250)	(5,269)
Net loss attributable to Fibrocell Science, Inc. common shareholders	\$ (1,711,515)	\$ (3,123,535)
Per share information:		
Loss from continuing operations-basic and diluted	\$ (0.09)	\$ (0.08)
Net loss attributable to common shareholders per common share basic and diluted	\$ (0.09)	\$ (0.08)

Edgar Filing: Fibrocell Science, Inc. - Form 10-Q

Weighted average number of basic and diluted common shares outstanding	19,468,831	38,384,120
---	------------	------------

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents**

**Fibrocell Science, Inc.**  
**(A Development Stage Company)**  
**Consolidated Statements of Operations**  
**(unaudited)**

	<b>Successor</b>	<b>Successor Cumulative period from September 1, 2009 (date of inception) to June 30, 2010</b>	<b>Predecessor</b>	<b>Predecessor Cumulative period from December 28, 1995 (date of inception) to August 31, 2009</b>
	<b>For the six months ended June 30, 2010</b>		<b>For the six months ended June 30, 2009</b>	
Revenue				
Product sales	\$ 473,132	\$ 803,073	\$ 407,880	\$ 4,818,994
License fees				260,000
Total revenue	473,132	803,073	407,880	5,078,994
Cost of sales	276,435	458,483	171,719	2,279,335
Gross profit	196,697	344,590	236,161	2,799,659
Impairment of long-lived assets				6,732,754
Selling, general and administrative expenses	3,841,243	6,549,599	2,268,415	78,072,766
Research and development expenses	2,666,351	4,489,547	1,493,207	56,269,869
Operating loss	(6,310,897)	(10,694,556)	(3,525,461)	(138,275,730)
Other income (expense)				
Interest income		1	247	6,989,539
Reorganization items, net	3,303	(69,174)	(593,204)	73,538,984
Other income				316,338
Warrant income (expense)	295,186	(23,898)		
Interest expense	(400,998)	(648,172)	(1,942,075)	(18,790,218)
Loss from continuing operations before income taxes	(6,413,406)	(11,435,799)	(6,060,493)	(76,221,087)
Income tax benefit				190,754
Loss from continuing operations	(6,413,406)	(11,435,799)	(6,060,493)	(76,030,333)
Loss from discontinued operations, net of tax	(29,546)	(41,659)	(169,280)	(41,091,311)
Net loss	(6,442,952)	(11,477,458)	(6,229,773)	(117,121,644)

Edgar Filing: Fibrocell Science, Inc. - Form 10-Q

Deemed dividend associated with beneficial conversion					(11,423,824)
Preferred stock dividends					(1,589,861)
Net income/(loss) attributable to noncontrolling interest	(16,388)	(31,881)	8,660		1,799,523
Net loss attributable to Fibrocell Science, Inc. common shareholders	\$ (6,459,340)	\$ (11,509,339)	\$ (6,221,113)	\$	(128,335,806)
Per share information:					
Loss from continuing operations-basic and diluted	\$ (0.37)	\$ (0.70)	\$ (0.16)	\$	(4.30)
Loss from discontinued operations-basic and diluted					(2.32)
Income attributable to noncontrolling interest					0.10
Deemed dividend associated with beneficial conversion of preferred stock					(0.65)
Preferred stock dividends					(0.09)
Net loss attributable to common shareholders per common share basic and diluted	\$ (0.37)	\$ (0.70)	\$ (0.16)	\$	(7.26)
Weighted average number of basic and diluted common shares outstanding	17,648,025	16,351,860	38,027,838		17,678,219

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents**

**Fibrocell Science, Inc.**  
**(A Development Stage Company)**  
**Consolidated Statements of Shareholders Equity (Deficit) and Comprehensive Income (Loss)**

									Accumulated		
	Series A	Series B							Deficit	Total	
	Preferred	Preferred	Common	Stock	Additional	Treasury	Other	During		Shareholders	
	Stock	Stock	Number	Number	Paid-In	Stock	Income	Development		Equity	
	Number	Number	of	of	Capital	Number	of	Stage		(Deficit)	
	of	of	Shares	Amount	Shares	of	Comprehensive				
	Shares	Shares				Amount	Income				
Issuance of common stock for cash on 12/28/95	\$	\$	2,285,291	\$ 2,285	\$ (1,465)	\$	\$	\$		\$	820
Issuance of common stock for cash on 11/7/96			11,149	11	49,989						50,000
Issuance of common stock for cash on 11/29/96			2,230	2	9,998						10,000
Issuance of common stock for cash on 12/19/96			6,690	7	29,993						30,000
Issuance of common stock for cash on 12/26/96			11,148	11	49,989					50,000	
Net loss								(270,468)		(270,468)	
Balance, 12/31/96 (Predecessor)	\$	\$	2,316,508	\$ 2,316	\$ 138,504	\$	\$	\$ (270,468)		\$ (129,648)	
Issuance of common stock for cash on 12/27/97			21,182	21	94,979						95,000
Issuance of common stock for services on 9/1/97			11,148	11	36,249						36,260
Issuance of common stock for services on 12/28/97			287,193	287	9,968					10,255	
Net loss								(52,550)		(52,550)	
Balance, 12/31/97 (Predecessor)	\$	\$	2,636,031	\$ 2,635	\$ 279,700	\$	\$	\$ (323,018)		\$ (40,683)	

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents**

	Series		Accumulated								
	A	B	Accumulated							Deficit	Total
	Preferred	Preferred	Common	Stock	Additional	Treasury	Stock	Other	During	Shareholders	
	Number of Shares	Number of Shares	Number of Shares	Amount	Paid-In Capital	Number of Shares	Amount	Comprehensive Income	Development Stage	Equity (Deficit)	
Issuance of common stock for cash on 8/23/98	\$	\$	4,459	\$ 4	\$ 20,063		\$	\$	\$	\$ 20,067	
Repurchase of common stock on 9/29/98						2,400	(50,280)			(50,280)	
Net loss									(195,675)	(195,675)	
Balance, 12/31/98 (Predecessor)	\$	\$	2,640,490	\$ 2,639	\$ 299,763	2,400	\$ (50,280)	\$	\$ (518,693)	\$ (266,571)	
Issuance of common stock for cash on 9/10/99			52,506	53	149,947					150,000	
Net loss									(1,306,778)	(1,306,778)	
Balance, 12/31/99 (Predecessor)	\$	\$	2,692,996	\$ 2,692	\$ 449,710	2,400	\$ (50,280)	\$	\$ (1,825,471)	\$ (1,423,349)	
Issuance of common stock for cash on 1/18/00			53,583	54	1,869					1,923	
Issuance of common stock for services on 3/1/00			68,698	69	(44)					25	
Issuance of common stock for services on 4/4/00			27,768	28	(18)					10	
Net loss									(807,076)	(807,076)	
Balance, 12/31/00	\$	\$	2,843,045	\$ 2,843	\$ 451,517	2,400	\$ (50,280)	\$	\$ (2,632,547)	\$ (2,228,467)	

(Predecessor)

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents**

	Series		Common Stock	Additional	Treasury	Accumulated				Total
	A Preferred Stock	B Preferred Stock				Accumulated	Deficit			
	Number of Shares	Number of Shares	Number of Shares	Paid-In Capital	Number of Shares	Stock Amount	Other Income	During Development Stage	Shareholders' Equity (Deficit)	
Issuance of common stock for services on 7/1/01	\$	\$	156,960	\$ 157	\$ (101)	\$	\$	\$	\$	56
Issuance of common stock for services on 7/1/01			125,000	125	(80)					45
Issuance of common stock for capitalization of accrued salaries on 8/10/01			70,000	70	328,055					328,125
Issuance of common stock for conversion of convertible debt on 8/10/01			1,750,000	1,750	1,609,596					1,611,346
Issuance of common stock for conversion of convertible shareholder notes payable on 8/10/01			208,972	209	135,458					135,667
Issuance of common stock for bridge financing on 8/10/01			300,000	300	(192)					108
Retirement of treasury stock on 8/10/01				(50,280)	(2,400)	50,280				
Issuance of common stock for net assets of Gemini on			3,942,400	3,942	(3,942)					

8/10/01				
Issuance of				
common stock				
for net assets				
of AFH on				
8/10/01	3,899,547	3,900	(3,900)	
Issuance of				
common stock				
for cash on				
8/10/01	1,346,669	1,347	2,018,653	2,020,000
Transaction				
and fund				
raising				
expenses on				
8/10/01			(48,547)	(48,547)
Issuance of				
common stock				
for services on				
8/10/01	60,000	60		60
Issuance of				
common stock				
for cash on				
8/28/01	26,667	27	39,973	40,000
Issuance of				
common stock				
for services on				
9/30/01	314,370	314	471,241	471,555

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents**

	Series A		Series B Preferred Stock		Common Stock	Accumulated			Deficit	Total
	Preferred Stock	Number of	Stock	Number of	Number of	Additional	Treasury	Other	During	Shareholders
	Number of	Shares	Number of	Shares	Shares	Paid-In	Stock	Comprehensive	Development	Equity
	Shares	Amount	Shares	Amount	Amount	Capital	Shares	Income	Stage	(Deficit)
Uncompensated contribution of services 3rd quarter		\$		\$	\$	\$ 55,556	\$	\$	\$	\$ 55,556
Issuance of common stock for services on 11/1/01					145,933	146	218,754			218,900
Uncompensated contribution of services 4th quarter						100,000				100,000
Net loss									(1,652,004)	(1,652,004)
Balance, 12/31/01 (Predecessor)		\$		\$	15,189,563	\$ 15,190	\$ 5,321,761	\$	\$	\$ (4,284,551) \$ 1,052,400
Uncompensated contribution of services 1st quarter						100,000				100,000
Issuance of preferred stock for cash on 4/26/02	905,000		905			2,817,331				2,818,236
Issuance of preferred stock for cash on 5/16/02	890,250		890			2,772,239				2,773,129
Issuance of preferred stock for cash on 5/31/02	795,000		795			2,473,380				2,474,175
Issuance of preferred stock for cash on 6/28/02	229,642		230			712,991				713,221
Uncompensated contribution of services 2nd						100,000				100,000

quarter									
Issuance of preferred stock for cash on 7/15/02	75,108	75			233,886			233,961	
Issuance of common stock for cash on 8/1/02			38,400	38	57,562			57,600	
Issuance of warrants for services on 9/06/02					103,388			103,388	
Uncompensated contribution of services 3rd quarter					100,000			100,000	
Uncompensated contribution of services 4th quarter					100,000			100,000	
Issuance of preferred stock for dividends	143,507	144			502,517		(502,661)		
Deemed dividend associated with beneficial conversion of preferred stock					10,178,944		(10,178,944)		
Comprehensive income:									
Net loss							(5,433,055)	(5,433,055)	
Other comprehensive income, foreign currency translation adjustment							13,875	13,875	
Comprehensive loss								(5,419,180)	
Balance, 12/31/02 (Predecessor)	3,038,507	\$ 3,039	\$ 15,227,963	\$ 15,228	\$ 25,573,999	\$ 13,875	\$ (20,399,211)	\$ 5,206,930	

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents**

	Series A		Series B		Common Stock		Additional		Treasury		Accumulated		Accumulated		Total
	Preferred Stock	Number of	Preferred Stock	Number of	Common Stock	Number of	Paid-In	Capital	Stock	Number	Other	Comprehensive	Development	Deficit	Shareholders' Equity (Deficit)
	Number of	Amount	Shares	Amount	Shares	Amount	Capital	Shares	Amount	Income	During	Stage			
		\$		\$	61,600	\$ 62	\$ 92,338	\$	\$		\$				\$ 9
					100,000	100	539,900								54
					(79,382)	(79)	(119,380)								(1)
							100,000								10
			110,250	110			2,773,218								2,7
			45,500	46			1,145,704								1,14
2nd qtr	(70,954)	(72)			147,062	147	40,626								4
2nd qtr					114,598	114	(114)								
							100,000								10
							1,244,880						(1,087,200)	(1,087,200)	(1,08

[illegible]

The accompanying notes are an integral part of these consolidated financial statements.



**Table of Contents**

	Series A Preferred Stock Number of Shares	Series B Preferred Stock Number of Shares	Common Stock Number of Shares	Common Stock Amount	Additional Paid-In Capital	Treasury Stock Number of Shares	Treasury Stock Amount	Accumulated		Total Shareholders' Equity (Deficit)
								Accumulated Other Comprehensive Income	Deficit During Development Stage	
Conversion of warrants into common stock \$1	\$	\$	78,526	\$ 79	\$ (79)		\$	\$	\$	\$
Balance of common stock for in connection with exercise of stock options \$1 qtr			15,000	15	94,985					95,000
Balance of common stock for in connection with exercise of warrants \$1 qtr			4,000	4	7,716					7,720
Compensation expense on warrants and warrants issued to employees										
Directors' \$1					1,410,498					1,410,498
Balance of common stock in connection with exercise of warrants \$1 qtr			51,828	52	(52)					
Balance of common stock for \$2 qtr			7,200,000	7,200	56,810,234					56,817,434
Compensation expense on warrants and warrants issued to employees										
Directors' \$2			7,431	7	143,462 (7)					143,462



alized gain

able-for-sale  
stments

prehensive

(21,384,

nce, 12/31/04

decessor) \$ \$ 34,194,899 \$ 34,195 \$ 109,935,174 4,000,000 \$ (25,974,000) \$ 464,110 \$ (55,474,054) \$ 28,985,

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents**

	Accumulated									
	Series A Preferred Stock Number of Shares	Series B Preferred Stock Number of Shares	Common Stock Number of Shares	Common Stock Amount	Additional Paid-In Capital	Treasury Stock Number of Shares	Treasury Stock Amount	Accumulated Other Comprehensive Income (Loss)	Deficit During Development Stage	Total Shareholders' Equity (Deficit)
Balance at December 31, 2013	1,000,000	1,000,000	25,000	\$ 250,000	\$ 74,975	—	\$ —	\$ —	\$ —	\$ 824,975
Issuance of common stock for cash	—	—	—	—	—	—	—	—	—	—
Issuance of common stock in connection with the sale of stock	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for compensation	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for services on	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for services and	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for services issued to	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for services employees	—	—	—	—	33,565	—	—	—	—	33,565
Conversion of preferred stock into common stock	—	—	27,785	277,785	(28)	—	—	—	—	277,757
Issuance of common stock for compensation	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for services on	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for services and	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for services issued to	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for services employees	—	—	—	—	(61,762)	—	—	—	—	(61,762)
Conversion of preferred stock into common stock	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for compensation	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for services on	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for services and	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for services issued to	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for services employees	—	—	—	—	(137,187)	—	—	—	—	(137,187)
Conversion of preferred stock into common stock	—	—	12,605	126,050	(12)	—	—	—	—	125,938
Issuance of common stock for compensation	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for services on	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for services and	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for services issued to	—	—	—	—	—	—	—	—	—	—
Issuance of common stock for services employees	—	—	—	—	18,844	—	—	—	—	18,844
Conversion of preferred stock into common stock	—	—	—	—	14,950	—	—	—	—	14,950



Table of Contents

Series A Preferred Stock Number of Shares	Series B Preferred Stock Number of Shares	Common Stock Number of Shares	Additional Paid-In Capital	Treasury Stock Number of Shares	Accumulated Other Comprehensive Income	Accumulated Deficit During Development Stage	Noncontrolling Interest
			\$ 42,810	\$	\$	\$	\$
			46,336				
		128,750	129	23,368			
			96,177				
			407,012				
			4,210				
		(97,400)	(97)	97			

ck				
with				
stock				
tr	10,000	10	16,490	
on				
ued				
ees 3				
on			25,627	
ds				
nd				
qtr			389,458	
on				
ock				
s 3			3,605	
ck				
with				
stock				
r	76,000	76	156,824	
of				
on				2,182,505
ued				
ees 4				
on			34,772	
ds				
nd				
qtr			390,547	
on			88	
ock				
s 4				

of

ock

ive

(15,002) (15) 15

ive

t

(35,821,406) (78,132) (

657,182

ive

)

\$ \$ 34,362,731 \$ 34,363 \$ 111,516,561 4,000,000 \$ (25,974,000) \$ (127,462) \$ (127,073,044) \$ 2,104,373 \$ (

The accompanying notes are an integral part of these consolidated financial statements.

## Table of Contents

ds					
and					
qtr					
on					
ock					
2 <sup>nd</sup> qtr			88		
on					
ds					
and					
qtr			478,795		
on					
ock					
3 <sup>rd</sup> qtr			88		
ock					
se of					
qtr	492,613	493	893,811		
ock					
t of					
ts 3 <sup>rd</sup>	6,767,647	6,767	13,745,400		1
ock					
with					
stock					
tr	1,666	2	3,164		
on					
ds					
and					
qtr			378,827		
on					
ock					
4 <sup>th</sup> qtr			88		
sive					
				(35,573,114)	(246,347)

846,388

ive  
n

sive

r)

\$ \$ 41,639,657 \$ 41,640 \$ 129,208,631 4,000,000 \$ (25,974,000) \$ 718,926 \$ (162,646,158) \$ 1,858,026 \$ (

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

Series A Preferred Stock	Series B Preferred Stock	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit		Noncontrolling Interest
						During	Development Stage	
Number of Shares	Number of Shares	Number of Shares	Amount	Number of Shares	Amount			
			\$ 44,849		\$		\$	\$
			151,305					
			1,262,815					
		(165)	(1)					
			62,697					
			193,754					
			166,687					
			171,012 (86,719)					

ted  
to  
s 4th

ion  
to

tr

e

n of  
ge  
ntial

e

e

08

\$ \$ 41,639,492 \$41,639 \$ 131,341,227 4,000,000 \$ (25,974,000) \$ \$(194,057,337) \$ 177,350  
The accompanying notes are an integral part of these consolidated financial statements.

166,196

(31,411,179) (1,680,676)

(2,152,569)

1,433,643

## Table of Contents

35

sive

1/09

(or)

n of

r common

resh start

s

of

r

d deficit

ulated

prehensive

/09

(r)

a shares

stock in

with

from

/09

shares of

ock in

with the

ng

common

ct. 28,

ion

shares

at

ion

option

ed to

ion

option

ed to

ees

6

(1

(12

12

\$

\$

\$

\$

\$

\$

\$

\$

\$

\$

\$

\$

\$

sive loss:

(5,049,999) 15,493

sive loss

31/09

\$ \$ 14,692,167 \$ 14,692 \$ 508,347 \$ \$ (5,049,999) \$ 398,475 \$

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents**

	Series A Preferred Stock Number of Shares	Series B Preferred Stock Number of Shares	Common Stock Number of Shares	Common Stock Amount	Additional Paid-In Capital	Treasury Stock Number of Shares	Accumulated			Total Equity (Deficit)
							Other	During	Noncontrolling	
							Income	Development	Interest	
							(Loss)	Stage		
Issuance of 5.1 million shares of common stock in March 2010, net of issuance costs of \$338,100 Warrant fair value associated with common shares issued in March 2010	\$	\$	5,076,664	\$ 5,077	\$ 3,464,323		\$	\$	\$	\$ 3,469,400
Compensation expense on shares issued to management 1Q10					(2,890,711)					(2,890,711)
Compensation expense on option awards issued to directors/employees-1Q10					18,000					18,000
Compensation expense on option awards issued to non-employees-1Q10					324,377					324,377
Compensation expense on shares issued to management 2Q10					18,391					18,391
Compensation expense on option awards issued to directors/employees-2Q10					18,000					18,000
Compensation expense on option awards issued to non-employees-2Q10					222,011					222,011
Comprehensive loss:					33,206					33,206
Net loss								(6,459,340)	16,388	(6,442,952)
Comprehensive loss										(6,442,952)
Balance 6/30/10 (Successor)	\$	\$	19,768,831	\$ 19,769	\$ 1,715,944	\$	\$	\$ (11,509,339)	\$ 414,863	\$ (9,358,763)

The accompanying notes are an integral part of these consolidated financial statements.



**Table of Contents**

**Fibrocell Science, Inc.**  
**(A Development Stage Company)**  
**Consolidated Statements of Cash Flows**  
**(unaudited)**

	<b>Successor</b>		<b>Predecessor</b>	
		<b>Cumulative period from September 1, 2009 (date of inception) to June 30, 2010</b>		<b>Cumulative period from December 28, 1995 (date of inception) to August 31, 2009</b>
	<b>Six months ended June 30, 2010</b>		<b>Six months ended June 30, 2009</b>	
Cash flows from operating activities:				
Net loss	\$ (6,459,340)	\$ (11,509,339)	\$ (6,221,113)	\$ (115,322,121)
Adjustments to reconcile net (loss) income to net cash used in operating activities:				
Reorganization items, net		72,477		(74,648,976)
Expense related to equity awards and issuance of stock	633,985	1,515,203	253,159	10,608,999
Warrant (income) expense	(295,187)	23,897		
Uncompensated contribution of services				755,556
Depreciation and amortization	3,140	3,140		9,091,990
Provision for doubtful accounts	(15,791)	(62,410)	(1,925)	337,810
Provision for excessive and/or obsolete inventory	(13,857)	(2,193)	(16,745)	259,427
Amortization of debt issue costs			803,187	4,107,067
Amortization of debt discounts on investments				(508,983)
Loss on disposal or impairment of property and equipment				17,668,477
Foreign exchange (gain) loss on substantial liquidation of foreign entity	4,334	1,720	35,714	(2,256,408)
Net loss (income) attributable to non-controlling interest	16,388	31,881	(8,660)	(1,799,523)
Change in operating assets and liabilities, excluding effects of acquisition:				
Decrease (increase) in accounts receivable	6,512	30,056	99,859	(91,496)
Decrease (increase) in other receivables	(96)	4,644	8,344	218,978
Decrease (increase) in inventory	6,111	37,034	36,542	(455,282)
Decrease (increase) in prepaid expenses	198,762	(46,143)	366,533	34,341
Decrease (increase) in other assets		4,120	(118,992)	71,000
Increase (decrease) in accounts payable	535,134	642,756	(176,477)	57,648
Increase in accrued expenses, liabilities subject to compromise and other liabilities	1,004,250	578,456	1,868,952	3,311,552
Decrease in deferred revenue			(7,522)	(50,096)

Net cash used in operating activities	(4,375,655)	(8,674,701)	(3,079,144)	(148,610,040)
Cash flows from investing activities:				
Acquisition of Agera, net of cash acquired				(2,016,520)
Purchase of property and equipment	(29,675)	(29,675)		(25,515,170)
Proceeds from the sale of property and equipment, net of selling costs				6,542,434
Purchase of investments				(152,998,313)
Proceeds from sales and maturities of investments				153,507,000
Net cash used in investing activities	(29,675)	(29,675)		(20,480,569)
Cash flows from financing activities:				
Proceeds from convertible debt				91,450,000
Offering costs associated with the issuance of convertible debt				(3,746,193)
Proceeds from notes payable to shareholders, net				135,667
Proceeds from the issuance of preferred stock, net				12,931,800
Proceeds from the issuance of redeemable preferred stock, net		2,870,000		
Proceeds from the issuance of common stock, net	3,469,400	5,269,400		93,753,857
Costs associated with secured loan and debtor-in-possession loan			(178,822)	(360,872)
Proceeds from secured loan			500,471	500,471
Proceeds from debtor-in-possession loan			1,000,000	2,750,000
Payments on insurance loan	(40,861)	(62,752)	(47,582)	(79,319)
Cash dividends paid on preferred stock	(91,000)	(91,000)		(1,087,200)
Cash paid for fractional shares of preferred stock				(38,108)
Merger and acquisition expenses				(48,547)
Repurchase of common stock				(26,024,280)
Net cash provided by financing activities	3,337,539	7,985,648	1,274,067	170,137,276

**Table of Contents**

	<b>Successor</b>		<b>Predecessor</b>	
		<b>Cumulative period from September 1, 2009 (date of inception) to June 30, 2010</b>		<b>Cumulative period from December 28, 1995 (date of inception) to August 31, 2009</b>
	<b>Six months ended June 30, 2010</b>		<b>Six months ended June 30, 2009</b>	
Effect of exchange rate changes on cash balances	(4,662)	(1,513)	(9,657)	(36,391)
Net increase (decrease) in cash and cash equivalents	(1,072,453)	(720,241)	(1,814,734)	1,010,276
Cash and cash equivalents, beginning of period	1,362,488	1,010,276	2,854,300	
Cash and cash equivalents, end of period	\$ 290,035	\$ 290,035	\$ 1,039,566	\$ 1,010,276
Supplemental disclosures of cash flow information:				
Predecessor cash paid for interest	\$	\$	\$	\$ 12,715,283
Successor cash paid for dividends	91,000	91,000		
Non-cash investing and financing activities:				
Predecessor deemed dividend associated with beneficial conversion of preferred stock	\$	\$	\$	\$ 11,423,824
Predecessor preferred stock dividend				1,589,861
Successor accrued preferred stock dividend	97,011	139,751		
Predecessor uncompensated contribution of services				755,556
Predecessor common stock issued for intangible assets				540,000
Predecessor common stock issued in connection with conversion of debt			10,814,000	10,814,000
				167,154

Predecessor equipment acquired through  
capital lease

Successor/Predecessor financing of insurance premiums	81,517	87,623
Successor issuance of notes payable		6,000,060
Successor common stock issued in connection with reorganization		5,472,000
Successor intangible assets		6,340,656
Successor deferred tax liability in connection with fresh-start		2,500,000
Elimination of Predecessor common stock and fresh start adjustment		14,780,320
Successor accrued warrant liability	2,890,711	3,206,903

The accompanying notes are an integral part of these consolidated financial statements.

**Table of Contents**

**Fibrocell Science, Inc.  
(A Development Stage Company)**

**Notes to Consolidated Financial Statements**

**Note 1 Emergence from Voluntary Reorganization Under Chapter 11 Proceedings and Reorganization Plan**

*Background*

On June 15, 2009 Isolagen, Inc. (the *Predecessor* ) and Isolagen's wholly owned subsidiary, Isolagen Technologies, Inc. ( *Isolagen Tech* ) (Isolagen and Isolagen Tech are referred as the *Debtors* ), each filed a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code (the *Bankruptcy Code* ) in the United States Bankruptcy Court for the District of Delaware in Wilmington (the *Bankruptcy Court* ) under Case Nos. 09-12072 and 09-12073, respectively.

On August 27, 2009 (the *Confirmation Date* ), the Bankruptcy Court entered an order (the *Confirmation Order* ) confirming the Debtors' Joint First Amended Plan of Reorganization dated July 30, 2009, as supplemented by the Plan Supplement dated August 21, 2009 (as so modified and supplemented, the *Plan* ). The effective date of the Plan ( *Effective Date* ) was September 3, 2009. Isolagen and Isolagen Tech emerged from bankruptcy as the reorganized debtors, Fibrocell Science, Inc. ( *Fibrocell* or the *Company* or the *Successor* ) and Fibrocell Technologies, Inc. ( *Fibrocell Technologies* ), respectively (collectively, the *Reorganized Debtors* ). Fibrocell now operates outside of the restraints of the bankruptcy process, free of the debts and liabilities discharged by the Plan.

The Predecessor Company's officers and directors as of the effective date were all deemed to have resigned and a new board of directors was appointed. As of the effective date, the Successor Company's initial board of directors consisted of: David Pernock, Paul Hopper and Kelvin Moore. Dr. Robert Langer was appointed to the Board in late September 2009. Declan Daly remained as chief operating officer and chief financial officer of the reorganized company, and in November 2009, he was appointed to the Board of Directors. Mr. Daly received 5% of the Common Stock of the Successor as of the date of his appointment, which is subject to a two-year vesting schedule whereby 50% vested on the Effective Date, 25% shall vest on the first anniversary and 25% shall vest on the second anniversary. Mr. Daly was the acting interim chief executive officer until February 1, 2010. On February 1, 2010, David Pernock became the Chief Executive Officer. Marc Mazur was appointed to the Board of Directors in April 2010. George J. Korkos, M.D., D.D.S., F.A.C.S. was appointed to the Board of Directors in July 2010.

*Plan of Reorganization*

Pursuant to the Plan, all of the Predecessor Company's equity interests, including without limitation its common stock, options and warrants outstanding as of the effective date were cancelled. On the effective date, the Successor Company completed an exit financing of common stock in the amount of \$2 million, after which the equity holders of the Successor Company were:

- 7,320,000 shares, to our pre-bankruptcy lenders and the lenders that provided us our debtor-in-possession facility, collectively;
- 3,960,000 shares, to the holders of our 3.5% convertible subordinated notes;
- 600,000 shares, to our management as of the effective date, which was our chief operating officer;
- 120,000 shares, to the holders of our general unsecured claims; and
- 2,666,666 shares, to the purchasers of shares in the \$2 million exit financing (our pre-bankruptcy lenders, the lenders that provided us our debtor-in-possession facility and the holders of our 3.5% convertible subordinated notes were permitted to participate in our exit financing).

## **Table of Contents**

In the Plan, in addition to the common stock set forth above, each holder of Isolagen's 3.5% convertible subordinated notes, due November 2024, in the approximate non-converted aggregate principal amount of \$81 million, received, in full and final satisfaction, settlement, release and discharge of and in exchange for any and all claims arising out of the 3.5% convertible subordinated notes, its pro rata share of an unsecured note in the principal amount of \$6 million, or the Notes. The Notes have the following features:

12.5% interest payable quarterly in cash or, at the Company's option, 15% payable in kind by capitalizing such unpaid amount and adding it to the principal as of the date it was due;  
matures June 1, 2012;

at any time prior to the maturity date, the Company may redeem any portion of the outstanding principal of the Notes in cash at 125% of the stated face value of the Notes; provided that the Company will be obligated to redeem all outstanding Notes upon the following events: (a) the Company or its subsidiary, Fibrocell Technologies, Inc. (formerly, Isolagen Technologies, Inc.) successfully complete a capital campaign raising in excess of \$10,000,000; or (b) the Company or its subsidiary, Fibrocell Technologies, Inc., are acquired by, or sell a majority stake to, an outside party;

the Notes contain customary representations, warranties and covenants, including a covenant that the Company and its subsidiary, Fibrocell Technologies, Inc., shall be prohibited from the incurrence of additional debt without obtaining the consent of 66 2/3% of the Note holders.

### *Trading of Common Stock*

The Predecessor's common stock ceased trading on the NYSE Amex on May 6, 2009 and in June 2009 the NYSE Amex delisted the Predecessor's common stock from listing on the NYSE Amex. Upon the Effective Date, the outstanding common stock of the Predecessor Company was cancelled for no consideration. Consequently, the Predecessor's stockholders prior to the Effective Date no longer have any interest as stockholders of the Predecessor Company by virtue of their ownership of the Predecessor's common stock prior to the emergence from bankruptcy. On October 21, 2009, the Successor Company was available for trading on the OTC Bulletin Board under the symbol FCSC.

## **Note 2 Basis of Presentation, Business and Organization**

Fibrocell is the parent company of Fibrocell Technologies and Agera Laboratories, Inc., a Delaware corporation (Agera). Fibrocell Technologies is the parent company of Isolagen Europe Limited, a company organized under the laws of the United Kingdom (Isolagen Europe), Isolagen Australia Pty Limited, a company organized under the laws of Australia (Isolagen Australia), and Isolagen International, S.A., a company organized under the laws of Switzerland (Isolagen Switzerland).

The Company is an aesthetic and therapeutic company focused on developing novel skin and tissue rejuvenation products. The Company's clinical development product candidates are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne and burns with a patient's own, or autologous, fibroblast cells produced in the Company's proprietary Fibrocell Process. The Company also markets an advanced skin care line with broad application in core target markets through its Agera subsidiary.

In October 2006, the Predecessor Company reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase III pivotal study protocol for the treatment of nasolabial fold wrinkles. The randomized, double-blind protocol was submitted to the FDA under the agency's Special Protocol Assessment (SPA) regulations. Pursuant to this assessment process, the FDA has agreed that the Predecessor Company's study design for two identical trials, including patient numbers, clinical endpoints, and statistical analyses, is acceptable to the FDA to form the basis of an efficacy claim for a marketing application. The randomized, double-blind, pivotal Phase III trials will evaluate the efficacy and safety of our product against placebo in approximately 400 patients with approximately 200 patients enrolled in each trial. The Predecessor Company completed enrollment of the study and commenced injection of subjects in early 2007. All injections were completed in January 2008 and top line results from this trial were publically announced in August 2008. The data analysis, including safety data, was publically released in October 2008. The related Biologics License Application (BLA) was submitted to the FDA in March 2009. In May 2009, the Predecessor Company announced that the FDA had completed its initial review of the Company's BLA related to its nasolabial fold wrinkles product candidate and that the FDA had accepted (or filed) the BLA for full review.



## **Table of Contents**

On October 9, 2009, the FDA Cellular, Tissue and Gene Therapies Advisory Committee reviewed the Company's nasolabial fold wrinkles product candidate. The Committee voted 11 yes to 3 no that the data presented on our product demonstrated efficacy, and 6 yes to 8 no that the data demonstrated safety; both for the proposed indication of treatment of nasolabial fold wrinkles. The Committee's recommendations are not binding on the FDA, but the FDA will consider their recommendations during their review of our application. The United States Adopted Names (USAN) Council adopted the USAN name, azficel-T, for our nasolabial fold wrinkles product candidate on October 28, 2009, and the FDA is currently evaluating a proposed brand name, Laviv.

On December 21, 2009, Fibrocell received a Complete Response letter from the FDA related to the BLA for azficel-T, an autologous cell therapy for the treatment of moderate to severe nasolabial fold wrinkles in adults. A Complete Response letter is issued by the FDA's Center for Biologics Evaluation and Research (CBER) when the review of a file is completed and additional data are needed prior to approval. The Complete Response letter requested that Fibrocell Science provide data from a histopathological study on biopsied tissue samples from patients following injection of azficel-T. The histology study (IT-H-001) will evaluate tissue treated with azficel-T as compared to tissue treated with sterile saline (placebo). The study will also provide information about the skin after treatment, including evaluation of collagen and elastin fibrils, and cellular structure of the sampled tissues. The Company submitted a proposed protocol concerning a histopathological study on biopsied samples to the FDA and to the Company's Investigational Review Board (IRB). The IRB has approved the protocol and the Company received the comments from the FDA on the protocol in May 2010.

On May 13, 2010, the Company announced the initiation of a small histology study of azficel-T, an autologous cell therapy currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe nasolabial fold wrinkles. The study has a target enrollment of approximately 20 participants from the completed and statistically significant pivotal Phase III studies of azficel-T (IT-R-005 and IT-R-006). The Company announced on July 8, 2010, the completion of enrollment of and first treatment visits for participants in its histology study of azficel-T. The second treatment visits for participants enrolled in the histology study of azficel-T were completed by the end of July.

The Complete Response letter also requested finalized Chemistry, Manufacturing and Controls (CMC) information regarding the manufacture of azficel-T as follow-up to discussions that occurred during the BLA review period, as well as revised policies and procedures.

### *Basis of Presentation*

For discussions on the results of operations, the Successor Company has compared the three and six months ended June 30, 2010 (Successor Company) to the three and six months ended June 30, 2009 (Predecessor Company). The Successor Company believes that the financial results provide management and investors a more meaningful analysis of the Successor Company's performance and trends for comparative purposes.

The consolidated financial statements and notes thereto presented herein are unaudited. In the opinion of management, all adjustments (consisting of normal accruals) have been made that are necessary to present fairly the financial position of the Company as of June 30, 2010, and the results of its operations and cash flows for the six months ended June 30, 2010 and the cumulative period from September 1, 2009 (date of inception) to June 30, 2010. These financial statements should be read in conjunction with the financial statements that were included in the Company's Annual Report on Form 10-K for the period ended December 31, 2009.

In June 2009, the Financial Accounting Standards Board (FASB) issued Accounting Standards Codification 105 (ASC), Generally Accepted Accounting Principles, which became the single source of authoritative nongovernmental U.S. generally accepted accounting principles (GAAP), superseding existing FASB, American Institute of Certified Public Accountants (AICPA), Emerging Issues Task Force (EITF), and related accounting literature. This pronouncement reorganizes the thousands of GAAP pronouncements into roughly 90 accounting topics and displays them using a consistent structure. Also included is relevant Securities and Exchange Commission (SEC) guidance organized using the same topical structure in separate sections and will be effective for financial statements issued for reporting periods that end after September 15, 2009. The impact on the Company's financial disclosures is that references to authoritative accounting literature will be references in accordance with ASC 105.



## **Table of Contents**

### *Financial Reporting by Entities in Reorganization under the Bankruptcy Code*

Overall, ASC 852-10, Financial Reporting by Entities in Reorganization Under the Bankruptcy Code, ( ASC 852 ) applies to the Company's financial statements for the periods that the Company operated under the provisions of Chapter 11. ASC 852 does not change the application of generally accepted accounting principles in the preparation of financial statements. However, for periods including and subsequent to the filing of the Chapter 11 petition, ASC 852 does require that the financial statements distinguish transactions and events that are directly associated with the reorganization from the ongoing operations of the business. Accordingly, certain revenues, expenses, gains, and losses that were realized or incurred during the Chapter 11 proceedings have been classified as reorganization items, net on the accompanying consolidated statements of operations.

As of September 1, 2009, the Successor Company adopted fresh-start accounting in accordance with ASC 852-10. The Successor Company selected September 1, 2009, as the date to effectively apply fresh-start accounting based on the absence of any material contingencies at the September 3, 2009 effective date and the immaterial impact of transactions between September 1, 2009 and September 3, 2009. The adoption of fresh-start accounting resulted in the Successor Company becoming a new entity for financial reporting purposes. The Successor Company is a development stage company in accordance with ASC 915, Development Stage Entities.

Accordingly, the financial statements prior to September 1, 2009 are not comparable with the financial statements for periods on or after September 1, 2009. References to Successor or Successor Company refer to the Company on or after September 1, 2009, after giving effect to the cancellation of Isolagen, Inc. common stock issued prior to the Effective Date, the issuance of new Fibrocell Science, Inc. common stock in accordance with the Plan, and the application of fresh-start accounting. References to Predecessor or Predecessor Company refer to the Company prior to September 1, 2009. See Note 5 Fresh-Start Accounting in the notes to these Consolidated Financial Statements for further details.

### **Note 3 Going Concern**

The Successor Company emerged from Bankruptcy in September 2009 and continues to operate as a going concern. At June 30, 2010, the Successor Company had cash and cash equivalents of approximately \$0.3 million and negative working capital of \$1.3 million. In early July 2010, the Successor Company raised approximately \$2.7 million less fees as a result of the issuance of preferred stock and warrants. The Successor Company believes that its existing capital resources are adequate to sustain its operation through approximately mid-September 2010. As such, the Successor Company will require additional cash resources prior to or during approximately mid-September 2010, or it will likely cease operations. The Successor Company will need to access the capital markets in the future in order to fund future operations. There is no guarantee that any such required financing will be available on terms satisfactory to the Successor Company or available at all. These matters create uncertainty relating to its ability to continue as a going concern. The accompanying consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or liabilities that might result from the outcome of these uncertainties. Further, if the Successor Company raises additional cash resources prior to mid-September 2010, it may be raised in contemplation of or in connection with bankruptcy. In the event of a bankruptcy, it is likely that its common stock and common stock equivalents will become worthless and our creditors will receive significantly less than what is owed to them.

Through June 30, 2010, the Successor Company has been primarily engaged in developing its initial product technology. In the course of its development activities, the Company has sustained losses and expects such losses to continue through at least 2010. During the six months ended June 30, 2010, the Successor Company financed its operations primarily through its existing cash, but as discussed above it now requires additional financing. There is substantial doubt about the Successor Company's ability to continue as a going concern.

## **Table of Contents**

The Successor Company's ability to complete additional offerings is dependent on the state of the debt and/or equity markets at the time of any proposed offering, and such market's reception of the Successor Company and the offering terms. The Successor Company's ability to complete an offering is also dependent on the status of its FDA regulatory milestones and its clinical trials, and in particular, the status of its indication for the treatment of nasolabial fold wrinkles and the status of the related BLA, which cannot be predicted. There is no assurance that capital in any form would be available to the Company, and if available, on terms and conditions that are acceptable.

As a result of the conditions discussed above, and in accordance with GAAP, there exists substantial doubt about the Successor Company's ability to continue as a going concern, and its ability to continue as a going concern is contingent, among other things, upon its ability to secure additional adequate financing or capital prior to or during approximately mid-September 2010. If the Successor Company does not obtain additional funding, or does not anticipate additional funding, prior to or during approximately mid-September 2010, it will likely enter into bankruptcy and/or cease operations. Further, if it does raise additional cash resources prior to mid-September 2010, it may be raised in contemplation of or in connection with bankruptcy. If the Successor Company enters into bankruptcy, it is likely that its common stock and common stock equivalents will become worthless and its creditors will receive significantly less than what is owed to them.

### **Note 4 Summary of Significant Accounting Policies**

#### *Use of Estimates*

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and notes. In addition, management's assessment of the Successor Company's ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Actual results may differ materially from those estimates.

#### *Cash and Cash Equivalents*

The Company considers highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

#### *Concentration of Credit Risk*

As of June 30, 2010, the Successor Company maintains the majority of its cash primarily with one major U.S. domestic bank. The amounts held in this bank do not exceed the insured limit of \$250,000. The terms of these deposits are on demand to minimize risk. The Successor Company has not incurred losses related to these deposits. Cash and cash equivalents of approximately \$0.2 million, related to Agera and the Successor Company's Swiss subsidiary, is maintained in two separate financial institutions. The Successor Company invests these funds primarily in demand deposit accounts.

#### *Allowance for Doubtful Accounts*

The Successor Company maintains an allowance for doubtful accounts related to its accounts receivable that have been deemed to have a high risk of collectability. Management reviews its accounts receivable on a monthly basis to determine if any receivables will potentially be uncollectible. One foreign customer represents 86% and 87% of accounts receivable, net, at June 30, 2010 and December 31, 2009, respectively. Management analyzes historical collection trends and changes in its customer payment patterns, customer concentration, and creditworthiness when evaluating the adequacy of its allowance for doubtful accounts. In its overall allowance for doubtful accounts, the Successor Company includes any receivable balances that are determined to be uncollectible. Based on the information available, management believes the allowance for doubtful accounts is adequate; however, actual write-offs might exceed the recorded allowance.

The allowance for doubtful accounts was \$21,307 and \$37,098 at June 30, 2010 and December 31, 2009, respectively.

## **Table of Contents**

### *Inventory*

Agera purchases the large majority of its inventory from one contract manufacturer. Agera accounts for its inventory on the first-in-first-out method. At June 30, 2010, Agera's inventory of \$0.2 million consisted of \$0.2 million of raw materials and less than \$0.1 million of finished goods. At December 31, 2009, Agera's inventory of \$0.2 million consisted of \$0.2 million of raw materials and less than \$0.1 million of finished goods.

### *Property and equipment*

Property and equipment is carried at cost less accumulated depreciation and amortization. Generally, depreciation and amortization for financial reporting purposes is provided by the straight-line method over the estimated useful life of three years, except for leasehold improvements which are amortized using the straight-line method over the remaining lease term or the life of the asset, whichever is shorter. The cost of repairs and maintenance is charged as an expense as incurred.

### *Intangible assets*

Intangible assets are research and development assets related to the Successor Company's primary study that was recognized upon emergence from bankruptcy (see Note 5). Intangibles are tested for recoverability whenever events or changes in circumstances indicate the carrying amount may not be recoverable. An impairment loss, if any, would be measured as the excess of the carrying value over the fair value determined by discounted cash flows. There was no impairment of the intangible assets as of June 30, 2010.

### *Revenue recognition*

The Successor Company recognizes revenue over the period the service is performed in accordance with ASC 605, Revenue Recognition (ASC 605). In general, ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services rendered, (3) the fee is fixed and determinable and (4) collectability is reasonably assured.

Revenue from the sale of Agera's products is recognized upon transfer of title, which is upon shipment of the product to the customer. The Successor Company believes that the requirements of ASC 605 are met when the ordered product is shipped, as the risk of loss transfers to our customer at that time, the fee is fixed and determinable and collection is reasonably assured. Any advanced payments are deferred until shipment.

### *Shipping and handling costs*

Agera charges its customers for shipping and handling costs. Such charges to customers are presented net of the costs of shipping and handling, as selling, general and administrative expense, and are not significant to the consolidated statements of operations.

### *Advertising cost*

Agera advertising costs are expensed as incurred and include the costs of public relations and certain marketing related activities. These costs are included in selling, general and administrative expenses in the accompanying consolidated statements of operations.

### *Research and development expenses*

Research and development costs are expensed as incurred and include salaries and benefits, costs paid to third-party contractors to perform research, conduct clinical trials, develop and manufacture drug materials and delivery devices, and a portion of facilities cost. Research and development costs also include costs to develop manufacturing, cell collection and logistical process improvements.

## **Table of Contents**

Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. Invoicing from third-party contractors for services performed can lag several months. The Successor Company accrues the costs of services rendered in connection with third-party contractor activities based on its estimate of management fees, site management and monitoring costs and data management costs. Actual clinical trial costs may differ from estimated clinical trial costs and are adjusted for in the period in which they become known.

### *Warrant Liability*

The warrants for the Successor Company are measured at fair value and liability-classified under ASC 815, Derivatives and Hedging, ( ASC 815 ) because the warrants contain down-round protection and therefore, do not meet the scope exception for treatment as a derivative under ASC 815. Since down-round protection is not an input into the calculation of the fair value of the warrants, the warrants cannot be considered indexed to the Company's own stock which is a requirement for the scope exception as outlined under ASC 815. The fair value of the warrants is determined using the Black-Scholes option pricing model and is affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. The Successor Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability.

### *Stock-based Compensation*

The Successor Company accounts for stock-based awards to employees and non-employees using the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. The Successor Company uses a Black-Scholes options-pricing model to determine the fair value of each option grant as of the date of grant for expense incurred. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. Expected volatility is based on historical volatility of the Company's competitor's stock since the Predecessor Company ceased trading as part of the bankruptcy and emerged as a new entity. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected lives for options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted. The Successor Company estimates future forfeitures of options based upon expected forfeiture rates.

### *Income taxes*

An asset and liability approach is used for financial accounting and reporting for income taxes. Deferred income taxes arise from temporary differences between income tax and financial reporting and principally relate to recognition of revenue and expenses in different periods for financial and tax accounting purposes and are measured using currently enacted tax rates and laws. In addition, a deferred tax asset can be generated by net operating loss ( NOLs ) carryover. If it is more likely than not that some portion or all of a deferred tax asset will not be realized, a valuation allowance is recognized.

In the event the Company is charged interest or penalties related to income tax matters, the Company would record such interest as interest expense and would record such penalties as other expense in the consolidated statements of operations. No such charges have been incurred by the Company. As of June 30, 2010 and December 31, 2009, the Successor Company had no accrued interest related to uncertain tax positions.

At June 30, 2010 and December 31, 2009, the Company has provided a full valuation allowance for the net deferred tax assets, the large majority of which relates to the future benefit of loss carryovers. In addition, as a result of fresh-start accounting, the Successor Company may be limited by section 382 of the Internal Revenue Service Code. The tax years 2006 through 2009 remain open to examination by the major taxing jurisdictions to which we are subject. The deferred tax liability at June 30, 2010 and December 31, 2009, relates to the intangible assets recognized upon fresh-start accounting.

## **Table of Contents**

### *Loss per share data*

Basic loss per share is calculated based on the weighted average common shares outstanding during the period. Diluted earnings per share ( Diluted EPS ) also gives effect to the dilutive effect of stock options, warrants, restricted stock and convertible preferred stock calculated based on the treasury stock method.

The Predecessor and Successor Company s potentially dilutive securities consist of potential common shares related to stock options, warrants, restricted stock and convertible preferred stock. Diluted EPS includes the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would be anti-dilutive. There were no potentially dilutive securities issued or outstanding for the six months ended June 30, 2010 and June 30, 2009.

### *Fair Value of Financial Instruments*

The carrying values of certain of the Successor Company s financial instruments, including cash equivalents and accounts payable approximates fair value due to their short maturities. The fair values of the Successor Company s long-term obligations are based on assumptions concerning the amount and timing of estimated future cash flows and assumed discount rates reflecting varying degrees of risk. The carrying values of the Successor Company s long-term obligations approximate their fair values.

The fair value of the reorganization value which applies in fresh-start accounting was estimated by applying the income approach and a market approach. This fair value measurement is based on significant inputs that are not observable in the market and, therefore, represents a Level 3 measurement as defined in ASC 820, Fair Value Measurements.

### *Adoption of Standards*

In March 2010, the FASB amended the disclosure requirements so that SEC filers are no longer required to disclose the date through which subsequent events have been evaluated in originally issued and revised financial statements. This revised guidance is effective immediately and we adopted this pronouncement on March 31, 2010 and have revised the disclosures as required.

On December 15, 2009, the FASB issued ASU No. 2010-06 Fair Value Measurements and Disclosures Topic 820

Improving Disclosures about Fair Value Measurements . This ASU requires some new disclosures and clarifies some existing disclosure requirements about fair value measurement as set forth in Codification Subtopic 820-10. The FASB s objective is to improve these disclosures and, thus, increase the transparency in financial reporting. The adoption of this ASU did not have a material impact on the Company s consolidated financial statements.

### **Note 5 Fresh-Start Accounting**

On September 1, 2009, the Successor Company adopted fresh-start accounting upon the emergence of bankruptcy in accordance with ASC 852-10, Reorganization. Fresh-start accounting results in the Company becoming a new entity for financial reporting purposes. Accordingly, the Company s consolidated financial statements for periods prior to September 1, 2009 are not comparable to consolidated financial statements presented on or after September 1, 2009. The Company selected September 1, 2009, as the date to apply fresh-start accounting based on the absence of any material contingencies at the September 3, 2009 effective date and the immaterial impact of transactions between September 1, 2009 and September 3, 2009.

Under ASC 852-10, the Successor Company must determine a value to be assigned to the equity of the emerging company as of the date of the adoption of fresh-start accounting. The Successor Company obtained an independent appraisal to value the equity and it served as the fair market value of the emerging Company s equity.

Fresh-start accounting reflects the value of the Successor Company as determined in the confirmed Plan. Under fresh-start accounting, the Successor Company s assets values are remeasured and allocated in conformity with ASC 805-20, Business Combinations, Identifiable Assets and Liabilities, and any Noncontrolling Interest. Fresh-start accounting also requires that all liabilities should be stated at fair value. The portion of the reorganization value which was attributed to identified intangible assets was \$6,340,656. This value is related to research and development assets that are not subject to amortization. In accordance with ASC 805-20, this amount is reported as intangibles in the consolidated financial statements as of June 30, 2010, and is not being amortized.



**Table of Contents**

The following fresh-start Consolidated Balance Sheet presents the financial effects on the Successor Company with the implementation of the Plan and the adoption of fresh-start accounting. The effect of the consummation of the transactions contemplated in the Plan included the settlement of liabilities and the issuance of common stock. The effects of the Plan and fresh-start reporting on the Successor Company's Consolidated Balance Sheet are as follows:

	<b>Predecessor</b>	<b>Reclassifications</b>	<b>Fresh Start</b>	<b>Successor</b>
	<b>August 31,</b>	<b>And Plan of</b>	<b>Accounting</b>	<b>September</b>
	<b>2009</b>	<b>Reorganization</b>	<b>Adjustments</b>	<b>1, 2009</b>
<b>Assets</b>				
<b>Current assets:</b>				
Cash and cash equivalents	\$ 1,010,277	\$	\$	\$ 1,010,277
Accounts receivable, net	246,684			246,684
Inventory, net	268,619			268,619
Prepaid expenses	221,225			221,225
Other current assets	4,140			4,140
Current assets of discontinued operations, net	785			785
Total current assets	1,751,730			1,751,730
Intangible assets			6,340,656(e)	6,340,656
Other assets	1,671			1,671
<b>Total assets</b>	<b>\$ 1,753,401</b>	<b>\$</b>	<b>\$ 6,340,656</b>	<b>\$ 8,094,057</b>
<b>Liabilities, Shareholders Equity/(Deficit) and Noncontrolling Interests</b>				
<b>Current liabilities:</b>				
Current debt	\$ 8,304	\$	\$	\$ 8,304
Accounts payable	137,401			137,401
Accrued expenses	849,395			849,395
Liabilities subject to compromise	82,181,741	(82,181,741)(a)		
Prepetition secured loan, subject to compromise	500,471	(500,471)(b)		
Debtor-in-possession loan	2,750,000	(2,750,000)(b)		
Current liabilities of discontinued operations	25,668			25,668
<b>Total current liabilities</b>	<b>86,452,980</b>	<b>(85,432,212)</b>		<b>1,020,768</b>
Other long term liabilities of continuing operations	407,078			407,078
Notes payable		6,000,060(a)		6,000,060

Deferred tax liability			2,500,000(f)	2,500,000
<b>Total liabilities</b>	86,860,058	(79,432,152)	2,500,000	9,927,906
Commitments and contingencies				
<b>Shareholders' Equity (Deficit):</b>				
Predecessor common stock	42,821	(42,821)(c)		
Predecessor additional paid-in capital	142,737,499	(25,931,179)(c)	(116,806,320)(g)	
Predecessor treasury stock	(25,974,000)	25,974,000(c)		
Successor common stock		11,400(a) (b)		11,400
Successor additional paid-in capital		5,460,600(a) (b)	(7,688,831)(g)	(2,228,231)
Accumulated deficit during development stage	(202,295,959)	73,960,152(a) (b) (c) (d)	128,335,807(g)	
Total shareholders' equity (deficit)	(85,489,639)	79,432,152	3,840,656	(2,216,831)
Noncontrolling interest	382,982			382,982
Total equity (deficit) and noncontrolling interests	(85,106,657)	79,432,152	3,840,656	(1,833,849)
<b>Total liabilities, shareholders' equity/(deficit) and noncontrolling interests</b>	<b>\$ 1,753,401</b>	<b>\$</b>	<b>\$ 6,340,656</b>	<b>\$ 8,094,057</b>

**Table of Contents**

**Notes to Plan of Reorganization and fresh-start accounting adjustments**

- (a) This adjustment reflects the discharge of liabilities subject to compromise in accordance with the Plan of Reorganization and the issuance of \$6 million in Notes payable and the issuance of 4,080,000 shares of Successor Company common stock in satisfaction of such claims.
- (b) This adjustment reflects the discharge of prepetition loan and debtor in-possession loan in accordance with the Plan of Reorganization and the issuance of 7,320,000 shares of the Successor Company common stock in satisfaction of such claims.
- (c) This adjustment reflects the cancellation of the Predecessor Company's common stock, additional

paid-in capital  
and treasury  
stock.

(d) To reset  
accumulated  
deficit to zero  
for the  
consolidated  
subsidiaries  
included in the  
Plan of  
Reorganization.

(e) This adjustment  
reflects the  
portion of the  
reorganization  
value which was  
attributed to  
identified  
intangible  
assets.

(f) To record  
deferred tax  
liability as a  
result of the  
impact of  
fresh-start  
accounting fair  
value  
adjustments.

(g) To reset  
Predecessor  
additional  
paid-in capital,  
accumulated  
deficit to zero  
and record net  
fresh-start  
adjustments.

**Note 6 Liabilities Subject to Compromise and Reorganization Items**

Liabilities subject to compromise refers to pre-petition obligations that were impacted by the Chapter 11 reorganization process. For further information regarding the discharge of liabilities subject to compromise, see Note 5- Fresh-Start Accounting in the notes of these Financial Statements. As of June 30, 2010, there were no liabilities subject to compromise.

The Company incurred certain professional fees and other expenses directly associated with the bankruptcy proceedings. In addition, the Company has made adjustments to the carrying value of certain prepetition liabilities. Such costs and adjustments are classified as reorganization items, net and are presented separately in the unaudited

consolidated statements of operations. There were no reorganization costs for the three months ended June 30, 2010. For the six months ended June 30, 2010, there was \$13K in professional fees offset by the gain from discharge of a liability of \$16K for a net gain of \$3K. For the three and six months ended June 30, 2009, there were \$199K in professional fees, \$113K in debt issuance costs related to DIP facility and \$281K in other debt issuance costs.

**Note 7 Agera Laboratories, Inc.**

On August 10, 2006, the Predecessor Company acquired 57% of the outstanding common shares of Agera. Agera is a skincare company that has proprietary rights to a scientifically-based advanced line of skincare products. Agera markets its product primarily in the United States and Europe. The results of Agera's operations and cash flows have been included in the consolidated financial statements from the date of the acquisition. The assets and liabilities of Agera have been included in the consolidated balance sheets since the date of the acquisition.

**Table of Contents****Note 8 Accrued Expenses**

Accrued expenses are comprised of the following:

	<b>Successor</b>	
	<b>June 30, 2010</b>	<b>December 31, 2009</b>
Accrued professional fees	\$ 469,852	\$ 147,410
Accrued compensation	291,959	7,208
Accrued interest	646,619	246,578
Dividend on preferred stock payable	48,750	42,740
Accrued other	157,307	100,324
Accrued expenses	\$ 1,614,487	\$ 544,260

**Note 9 Equity***Common Stock Offering*

On March 2, 2010, the Company entered into a Securities Purchase Agreement (the *Purchase Agreement*) with certain accredited investors (the *Purchasers*), pursuant to which the Company sold to the Purchasers in the aggregate 5,076,664 shares of common stock at a purchase price of \$0.75 per share. Each Purchaser also received a warrant to purchase the same number of shares of common stock acquired in the offering at an exercise price of \$0.98 per share (the *Warrants*).

The aggregate purchase price paid by the Purchasers for the common stock and the warrants was \$3,807,500. The Company used the proceeds for working capital purposes.

Viriathus Capital LLC and John Carris Investments LLC were co-placement agents for the transaction, and received cash compensation of \$304,600 and warrants to purchase 406,133 shares of common stock at an exercise price of \$0.75 per share upon the closing.

*Redeemable Preferred Stock*

In October 2009, the Successor Company completed an offering of Series A Preferred Stock, Class A Warrants and Class B Warrants (the *October 2009 Offering*). Each of the foregoing securities were subject to the down-round protection, which provisions require the lowering of the conversion price or exercise price, as applicable, to the purchase price in the current offering, or \$0.75, and with respect to the warrants, the number of shares issuable under the warrants issued in the October 2009 Offering will be proportionately increased such that the aggregate exercise price payable, after taking into consideration the decrease in exercise price, shall be equal to the aggregate exercise price prior to such adjustment. The preferred stock has been classified within the mezzanine section between liabilities and equity in its consolidated balance sheets because any holder of Series A Preferred Stock may require the Successor Company to redeem all of its Series A Preferred Stock in the event of a triggering event which is outside of the control of the Successor Company. The Successor Company records accrued dividends at a rate of 6% per annum on the Series A Preferred stock. A dividend payment of \$91,000 was paid in April 2010 for the dividends accrued as of March 31, 2010. As of June 30, 2010, \$48,750 is accrued for dividends payable.

**Note 10 Warrants***Class A and B Warrants and Placement Agent Warrants*

As disclosed above in Note 9, the Successor Company issued Class A warrants, Class B warrants and placement agent warrants in connection with the October 2009 preferred stock transaction. The warrants are liability classified since they have down-round price protection and they are re-measured on the Company's reporting dates. As a result of the March 2, 2010 common stock financing and the down-round provision, the Class A warrants, Class B warrants and placement agent warrants were reissued to purchase 2.6 million shares of Common Stock at an exercise price of \$0.75 per share.

*Common Stock Warrants and Co-placement Agent Warrants*

In connection with the March 2, 2010 financing, the Successor Company issued 5,076,664 warrants at an exercise price of \$0.98 per share to the accredited investors and 406,133 warrants at an exercise price of \$0.75 to the co-placement agents upon closing. The warrants are liability classified since they have down-round price protection and they are re-measured on the Company's reporting dates. The warrants were exercisable immediately after grant and expire five years thereafter. The fair market value of the warrants, at the date of issuance, granted to the accredited investors and co-placement agents, based on the Black-Scholes valuation model, is estimated to be \$0.52 per warrant and \$0.58 per warrant, respectively.

**Table of Contents**

The Successor Company recognizes these warrants as a liability at the fair value on each reporting date due to the down-round price protection provision. The Company measured the fair value of these warrants as of June 30, 2010, and recorded warrant income of \$1.7 million resulting from the decrease in the liability associated with the fair value of the warrants for the three months ended June 30, 2010. The Company computed the value of the warrants using the Black-Scholes method. The fair value of the warrants will continue to be classified as a liability until such time as the warrants are exercised, expire or an amendment of the warrant agreements renders these warrants to be no longer classified as a liability.

The fair market value of the warrants was computed using the Black-Scholes option-pricing model with the following key assumptions as of the dates indicated:

	<b>June 30, 2010</b>
Expected life (years)	4.3-4.7 years
Interest rate	1.8%
Dividend yield	
Volatility	64%
Warrant liability is comprised of the following as of June 30, 2010:	

	Number of Warrants	Successor Fair Value of Warrants	Balance as of June 30, 2010
Preferred Stock Class A Warrants	1,083,333	\$ 0.42	\$ 457,352
Preferred Stock Class B Warrants	1,083,334	0.42	457,353
Preferred Stock Co-placement	433,333	0.42	182,942
Common Stock Warrants	5,076,667	0.39	1,955,424
Common Stock Placement Warrants	406,333	0.44	177,729
Total	8,083,000		\$ 3,230,800

Warrant liability is comprised of the following as of December 31, 2009:

	Number of Warrants	Successor Fair Value of Warrants	Balance as of December 31, 2009
Preferred Stock Class A Warrants	501,543	\$ 0.55	\$ 275,378
Preferred Stock Class B Warrants	416,667	0.50	207,611
Preferred Stock Co-placement	250,000	0.61	152,287
Total	1,168,210		\$ 635,276

**Note 11 Equity-based Compensation**

Total stock-based compensation expense recognized using the straight-line attribution method in the consolidated statement of operations is as follows:

Successor Three months ended	Successor Six months ended
------------------------------------	----------------------------------

Edgar Filing: Fibrocell Science, Inc. - Form 10-Q

	<b>June 30, 2010</b>	<b>June 30, 2010</b>
Stock option compensation expense for employees and directors	\$ 222,011	\$ 546,388
Restricted stock expense	18,000	36,000
Equity awards for nonemployees issued for services	33,206	51,597
Total stock-based compensation expense	\$ 273,217	\$ 633,985

**Table of Contents**

On February 23, 2010, modifications were made to all fiscal year 2009 grants for directors and employees. The modifications provided for all options granted under the 2009 Plan in fiscal year 2009 to extend to a ten year term and allowed Directors to extend the exercise period after departure to one year. As a result of the modifications, the Successor Company recognized incremental compensation cost of approximately \$156,000 in the six months ended June 30, 2010.

On February 1, 2010, the Successor Company granted options to purchase 1,650,000 shares of common stock to the chief executive officer. The weighted average fair market value using the Black-Scholes option-pricing model of these options granted was \$0.63.

On April 1, 2010 and June 16, 2010, the Successor Company granted options to purchase 800,000 shares of common stock to a director and consultants. The weighted average fair market value using the Black-Scholes option-pricing model of these options granted was \$0.46. The fair market value of the stock options at the date of grant was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions:

	<b>Successor Three Months Ended June 30, 2010</b>
Expected life (years)	3.7 years
Interest rate	1.6%
Dividend yield	
Volatility	64%

There were no stock options exercised during the three and six months ended June 30, 2010.

The total fair value of shares vested during the second quarter 2010 was \$0.1 million. As of June 30, 2010, there was \$0.8 million of total unrecognized compensation cost, related to non-vested stock options which vest over time. That cost is expected to be recognized over a weighted-average period of 2.3 years. As of June 30, 2010, there was \$0.4 million of total unrecognized compensation expense related to performance-based, non-vested employee and consultant stock options. That cost will be recognized when the performance criteria within the respective performance-based option grants become probable of achievement.

*Restricted stock*

As of June 30, 2010, there was \$0.1 million of total unrecognized compensation cost related to non-vested restricted stock that is expected to be recognized over a weighted-average period of 1.17 years.

*Predecessor Company*

Prior to September 3, 2009, the Predecessor Company maintained stock-based incentive compensation plans for employees and directors of the Company. On the Effective Date, the following stock option plans were terminated (and any and all awards granted under such plans were terminated and will no longer be of any force or effect): (1) the 2001 Stock Option and Appreciation Rights Plan, (2) the 2003 Stock Option and Appreciation Rights Plan, and (3) the 2005 Stock Option and Appreciation Rights Plan.

**Table of Contents****Note 12 Segment Information and Geographical information**

The Successor Company has two reportable segments: Fibrocell Therapy and Agera. The Fibrocell Therapy segment specializes in the development and commercialization of autologous cellular therapies for soft tissue regeneration. The Agera segment maintains proprietary rights to a scientifically-based advanced line of skincare products. There is no intersegment revenue. The following table provides operating financial information for the continuing operations of the Successor Company's two reportable segments:

	<b>Segment</b>		<b>Successor</b>
	<b>Successor Fibrocell Therapy</b>	<b>Agera</b>	<b>Consolidated</b>
<b>Three Months Ended June 30, 2010</b>			
Total operating revenue	\$	\$ 264,062	\$ 264,062
Segment loss from continuing operations	\$ (1,676,370)	\$ (21,393)	\$ (1,697,763)

**Supplemental information related to continuing operations**

Depreciation and amortization expense	\$ 2,288	\$	\$ 2,288
---------------------------------------	----------	----	----------

	<b>Segment</b>		<b>Successor</b>
	<b>Successor Fibrocell Therapy</b>	<b>Agera</b>	<b>Consolidated</b>
<b>Six Months Ended June 30, 2010</b>			
Total operating revenue	\$	\$ 473,132	\$ 473,132
Segment loss from continuing operations	\$ (6,402,918)	\$ (10,488)	\$ (6,413,406)

**Supplemental information related to continuing operations**

Depreciation and amortization expense	\$ 3,140	\$	\$ 3,140
Total assets as of June 30, 2010	6,858,898	641,244	7,500,142
Property and equipment, net	26,535		26,535
Intangible assets	6,340,656		6,340,656

An intercompany receivable as of June 30, 2010, of \$1.0 million, due from the Agera segment to the Fibrocell Therapy segment, is eliminated in consolidation. This intercompany receivable is primarily due to the intercompany management fee charge to Agera by Fibrocell Technologies, as well as Agera working capital needs provided by Fibrocell Technologies, and has been excluded from total assets of the Fibrocell Therapy segment in the above table. There is no intersegment revenue. Total assets on the consolidated balance sheet at June 30, 2010 are approximately \$7.5 million.

	<b>Segment</b>		<b>Predecessor</b>
	<b>Predecessor Isolagen Therapy</b>	<b>Agera</b>	<b>Consolidated</b>
<b>Three Months Ended June 30, 2009</b>			
Total operating revenue	\$	\$ 248,991	\$ 248,991
Segment loss from continuing operations	\$ (2,952,319)	\$ (23,167)	\$ (2,975,486)

	<b>Segment</b>		
	<b>Predecessor Isolagen Therapy</b>	<b>Agera</b>	<b>Predecessor Consolidated</b>
<b>Six Months Ended June 30, 2009</b>			
Total operating revenue	\$	\$ 407,880	\$ 407,880
Segment loss from continuing operations	\$ (5,967,059)	\$ (93,434)	\$ (6,060,493)

**Supplemental information related to continuing operations**

Depreciation and amortization expense	\$	\$	\$
Total assets, including assets from discontinued operations as of June 30, 2009	1,428,547	810,744	2,239,291
Property and equipment, net			
Intangible assets, net			

**Table of Contents**

An intercompany receivable of \$0.9 million, due from the Agera segment to the Isolagen Therapy segment as of June 30, 2009, is eliminated in consolidation. This intercompany receivable is primarily due to the intercompany management fee charge to Agera by Isolagen, as well as Agera working capital needs provided by Isolagen, and has been excluded from total assets of the Isolagen Therapy segment in the above table. Total assets on the consolidated balance sheet at June 30, 2009 are approximately \$2.2 million, which includes assets of discontinued operations of less than \$0.1 million.

Geographical information concerning the Successor Company's and Predecessor Company's operations and assets are as follows:

	<b>Revenue Successor Three months ended June 30, 2010</b>	<b>Revenue Predecessor Three months ended June 30, 2009</b>
United States	\$ 61,654	\$ 73,143
United Kingdom	149,123	165,067
Other	53,285	10,781
	<b>\$ 264,062</b>	<b>\$ 248,991</b>

	<b>Revenue Successor Six months ended June 30, 2010</b>	<b>Revenue Predecessor Six months ended June 30, 2009</b>
United States	\$ 121,848	\$ 146,633
United Kingdom	290,790	224,111
Other	60,494	37,136
	<b>\$ 473,132</b>	<b>\$ 407,880</b>

During the three months ended June 30, 2010, revenue from one foreign customer and one domestic customer represented 75% and 16% of consolidated revenue, respectively. During the three months ended June 30, 2009, revenue from one foreign customer and one domestic customer represented 66% and 20% of consolidated revenue, respectively.

During the six months ended June 30, 2010, revenue from one foreign customer and one domestic customer represented 72% and 18% of consolidated revenue, respectively. During the six months ended June 30, 2009, revenue from one foreign customer and one domestic customer represented 55% and 24% of consolidated revenue, respectively.

As of June 30, 2010 and December 31, 2009, one foreign customer represented 86% and 87%, respectively, of accounts receivable, net.

**Note 13 Subsequent Events**

The Company submitted on August 9, 2010, a clinical study report for its Phase II/III study of azficel-T for the treatment of moderate to severe acne scars to the U.S. Food & Drug Administration.



**Table of Contents**

Effective July 20, 2010, the board of directors of the Company approved the appointment of George J. Korkos, M.D., D.D.S., F.A.C.S. to the Company's board of directors. On his appointment, Dr. Korkos received an option to purchase 200,000 shares of Company common stock at an exercise price equal to the fair market value of the Company's common stock on the date of issuance, of which 100,000 shares vest immediately and 100,000 shares vest in twelve months.

On July 16, 2010, the Company entered into a Securities Purchase Agreement with certain accredited investors pursuant to which the Company agreed to sell to the Purchasers in the aggregate: (i) 2,702 shares of Series B Convertible Preferred Stock, with a par value of \$0.001 per share and a stated value of \$1,000 per share (Series B Preferred), and (ii) warrants to purchase 4,503,334 shares of Company common stock (Common Stock) at an exercise price of \$0.8054 per share (the Warrants).

The aggregate purchase price paid by the Purchasers for the Series B Preferred and the Warrants was \$2,702,000 (representing \$1,000 for each share of Series B Preferred together with the Warrants). The Company intends to use the proceeds for working capital purposes.

Viriathus Capital LLC and John Carris Investments LLC were co-placement agents for the Transaction, and received, in the aggregate, cash compensation of \$216,160 and warrants to purchase 360,267 shares of Common Stock at an exercise price of \$0.60 per share.

With the completion of the July 2010 financing, the Series A Preferred Stock, completed in October 2009 and the common stock financing, completed in March 2010, are both subject to the down-round protection provision which will require the lowering of the conversion price or exercise price, as applicable, to the shares and warrants. Due to the anti-dilution provisions in the warrants, the number of shares underlying the warrants will also be proportionately increased.

**Table of Contents**

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.**

**The following discussion and analysis should be read in conjunction with our consolidated financial statements, including the notes thereto.**

**Forward-Looking Information**

This report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, as well as information relating to Fibrocell that is based on management's exercise of business judgment and assumptions made by and information currently available to management. When used in this document and other documents, releases and reports released by us, the words anticipate, believe, estimate, expect, intend, the facts suggest and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect our current view of future events and are subject to certain risks and uncertainties as noted below. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results could differ materially from those anticipated in these forward-looking statements. Actual events, transactions and results may materially differ from the anticipated events, transactions or results described in such statements. Although we believe that our expectations are based on reasonable assumptions, we can give no assurance that our expectations will materialize. Many factors could cause actual results to differ materially from our forward looking statements. Several of these factors include, without limitation:

- our ability to finance our business and continue in operations;
- whether the results of our full Phase III pivotal study and our BLA filing will result in approval of our product candidate, and whether any approval will occur on a timely basis;
- our ability to meet requisite regulations or receive regulatory approvals in the United States, Europe, Asia and the Americas, and our ability to retain any regulatory approvals that we may obtain; and the absence of adverse regulatory developments in the United States, Europe, Asia and the Americas or any other country where we plan to conduct commercial operations;
- whether our clinical human trials relating to the use of autologous cellular therapy applications, and such other indications as we may identify and pursue can be conducted within the timeframe that we expect, whether such trials will yield positive results, or whether additional applications for the commercialization of autologous cellular therapy can be identified by us and advanced into human clinical trials;
- our ability to develop autologous cellular therapies that have specific applications in cosmetic dermatology, and our ability to explore (and possibly develop) applications for periodontal disease, reconstructive dentistry, treatment of restrictive scars and burns and other health-related markets;
- our ability to decrease our manufacturing costs for our Fibrocell Therapy product candidates through the improvement of our manufacturing process, and our ability to validate any such improvements with the relevant regulatory agencies;
- our ability to reduce our need for fetal bovine calf serum by improved use of less expensive media combinations and different media alternatives;
- continued availability of supplies at satisfactory prices;
- new entrance of competitive products or further penetration of existing products in our markets;
- the effect on us from adverse publicity related to our products or the company itself;
- any adverse claims relating to our intellectual property;
- the adoption of new, or changes in, accounting principles;
- our issuance of certain rights to our shareholders that may have anti-takeover effects;
- our dependence on physicians to correctly follow our established protocols for the safe administration of our Fibrocell Therapy; and
- other risks referenced from time to time elsewhere in this prospectus and in our filings with the SEC.



## **Table of Contents**

These factors are not necessarily all of the important factors that could cause actual results of operations to differ materially from those expressed in these forward-looking statements. Other unknown or unpredictable factors also could have material adverse effects on our future results. We undertake no obligation and do not intend to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated events. We cannot assure you that projected results will be achieved.

## **Overview**

We are an aesthetic and therapeutic development stage biotechnology company focused on developing novel skin and tissue rejuvenation products. Our clinical development product candidates are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne and burn scars with a patient's own, or autologous, fibroblast cells produced by our proprietary Fibrocell process. Our clinical development programs encompass both aesthetic and therapeutic indications. Our most advanced indication is for the treatment of nasolabial folds wrinkles (United States adopted name, or USAN, is azficel-T) and has completed Phase III clinical studies, and the related Biologics License Application, or BLA, has been submitted to the Food and Drug Administration, or FDA. In October 2009, the FDA's Cellular, Tissue and Gene Therapies Advisory Committee reviewed this indication. On December 21, 2009, Fibrocell received a Complete Response letter from the FDA related to the BLA for azficel-T, an autologous cell therapy for the treatment of moderate to severe nasolabial fold wrinkles in adults. A Complete Response letter is issued by the FDA's Center for Biologics Evaluation and Research (CBER) when the review of a file is completed and additional data are needed prior to approval. The Complete Response letter requested that Fibrocell Science provide data from a histopathological study on biopsied tissue samples from patients following injection of azficel-T. The histology study (IT-H-001) will evaluate tissue treated with azficel-T as compared to tissue treated with sterile saline (placebo). The study will also provide information about the skin after treatment, including evaluation of collagen and elastin fibrils, and cellular structure of the sampled tissues. The Company submitted a proposed protocol concerning a histopathological study on biopsied samples to the FDA and to the Company's Investigational Review Board (IRB). The IRB has approved the protocol and the Company received the comments from the FDA on the protocol in May 2010.

On May 13, 2010, the Company announced the initiation of a small histology study of azficel-T, an autologous cell therapy currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe nasolabial fold wrinkles. The study has a target enrollment of approximately 20 participants from the completed and statistically significant pivotal Phase III studies of azficel-T (IT-R-005 and IT-R-006). The Company announced on July 8, 2010, the completion of enrollment of and first treatment visits for participants in its histology study of azficel-T. The second treatment visits for participants enrolled in the histology study of azficel-T were completed by the end of July.

The Complete Response letter also requested finalized Chemistry, Manufacturing and Controls (CMC) information regarding the manufacture of azficel-T as follow-up to discussions that occurred during the BLA review period, as well as revised policies and procedures.

During 2009 we completed a Phase II/III study for the treatment of acne scars. During 2008 we completed our open-label Phase II study related to full face rejuvenation.

## **Table of Contents**

We also develop and market an advanced skin care product line through our Agera subsidiary, in which we acquired a 57% interest in August 2006.

### **Exit from Bankruptcy**

On August 27, 2009, the United States Bankruptcy Court for the District of Delaware in Wilmington entered an order, or Confirmation Order, confirming the Joint First Amended Plan of Reorganization dated July 30, 2009, as supplemented by the Plan Supplement dated August 21, 2009, or the Plan, of Isolagen, Inc. and Isolagen's wholly owned subsidiary, Isolagen Technologies, Inc. The effective date of the Plan was September 3, 2009. Isolagen, Inc. and Isolagen Technologies, Inc. were subsequently renamed Fibrocell Science, Inc. and Fibrocell Technologies, Inc., respectively.

Pursuant to the Plan, all our equity interests, including without limitation our common stock, options and warrants outstanding as of the effective date were cancelled. On the effective date, we completed an exit financing of common stock in the amount of \$2 million, after which the equity holders of our Successor Company were:

- 7,320,000 shares, to our pre-bankruptcy lenders and the lenders that provided us our debtor-in-possession facility, collectively;
- 3,960,000 shares, to the holders of our 3.5% convertible subordinated notes;
- 600,000 shares, to our management as of the effective date, which was our chief operating officer;
- 120,000 shares, to the holders of our general unsecured claims; and
- 2,666,666 shares, to the purchasers of shares in the \$2 million exit financing (our pre-bankruptcy lenders, the lenders that provided us our debtor-in-possession facility and the holders of our 3.5% convertible subordinated notes were permitted to participate in our exit financing).

In the Plan, in addition to the common stock set forth above, each holder of Isolagen's 3.5% convertible subordinated notes, due November 2024, in the approximate non-converted aggregate principal amount of \$81 million, received, in full and final satisfaction, settlement, release and discharge of and in exchange for any and all claims arising out of the 3.5% convertible subordinated notes, its *pro rata* share of an unsecured note in the principal amount of \$6 million, or the Notes. The Notes have the following features:

12.5% interest payable quarterly in cash or, at our option, 15% payable in kind by capitalizing such unpaid amount and adding it to the principal as of the date it was due;

matures June 1, 2012;

at any time prior to the maturity date, we may redeem any portion of the outstanding principal of the Notes in cash at 125% of the stated face value of the Notes; provided that we will be obligated to redeem all outstanding Notes upon the following events: (a) we or our subsidiary, Fibrocell Technologies, Inc. (formerly, Isolagen Technologies, Inc.) successfully complete a capital campaign raising in excess of \$10,000,000; or (b) we or our subsidiary, Fibrocell Technologies, Inc., are acquired by, or sell a majority stake to, an outside party;

the Notes contain customary representations, warranties and covenants, including a covenant that we and our subsidiary, Fibrocell Technologies, Inc., shall be prohibited from the incurrence of additional debt without obtaining the consent of 66 2/3% of the Note holders.

### **Going Concern**

The Successor Company emerged from Bankruptcy in September 2009 and continues to operate as a going-concern. At June 30, 2010, we had cash and cash equivalents of approximately \$0.3 million and negative working capital of \$1.3 million. In early July 2010, we raised approximately \$2.7 million less fees as a result of the issuance of preferred stock and warrants. We believe that our existing capital resources are adequate to sustain our operation through approximately mid-September 2010. As such, we will require additional cash resources prior to or during approximately mid-September 2010, or we will likely cease operations. The Successor Company will need to access the capital markets in the future in order to fund future operations. There is no guarantee that any such required financing will be available on terms satisfactory to the Successor Company or available at all. These matters create uncertainty relating to our ability to continue as a going concern. The accompanying consolidated financial statements

do not reflect any adjustments relating to the recoverability and classification of assets or liabilities that might result from the outcome of these uncertainties.

## **Table of Contents**

Through June 30, 2010, we have been primarily engaged in developing our initial product technology. In the course of our development activities, we have sustained losses and expect such losses to continue through at least 2010. Our ability to complete additional offerings is dependent on the state of the debt and/or equity markets at the time of any proposed offering, and such market's reception of the Successor Company and the offering terms. Our ability to complete an offering is also dependent on the status of our FDA regulatory milestones and our clinical trials, and in particular, the status of our indication for the treatment of nasolabial fold wrinkles and the status of the related BLA, which cannot be predicted. There is no assurance that capital in any form would be available to us, and if available, on terms and conditions that are acceptable.

As a result of the conditions discussed above, and in accordance with generally accepted accounting principles in the United States, there exists substantial doubt about our ability to continue as a going concern, and our ability to continue as a going concern is contingent, among other things, upon our ability to secure additional adequate financing or capital prior to or during approximately mid- September 2010. If we do not obtain additional funding, or do not anticipate additional funding, prior to or during approximately mid- September 2010, we will likely enter into bankruptcy and/or cease operations. Further, if we do raise additional cash resources prior to mid- September 2010, it may be raised in contemplation of or in connection with bankruptcy. If we enter into bankruptcy, it is likely that our common stock and common stock equivalents will become worthless and our creditors will receive significantly less than what is owed to them.

### **Clinical Development Programs**

Our product development programs are focused on the aesthetic and therapeutic markets. These programs are supported by a number of clinical trial programs at various stages of development.

Our aesthetics development programs include product candidates to treat targeted areas or wrinkles and to provide full-face rejuvenation that includes the improvement of fine lines, wrinkles, skin texture and appearance. Our therapeutic development programs are designed to treat acne scars, restrictive burn scars and dental papillary recession. All of our product candidates are non-surgical and minimally invasive. Although the discussions below may include estimates of when we expect trials to be completed, the prediction of when a clinical trial will be completed is subject to a number of factors and uncertainties. Also, please refer to Part I, Item 1A of our Form 10-K for the year ended December 31, 2009, for a discussion of certain of our risk factors related to our clinical development programs, as well as other risk factors related to our business.

#### *Aesthetic Development Programs*

**Nasolabial Fold Wrinkles Phase III Trials:** In October 2006, we reached an agreement with the FDA, on the design of a Phase III pivotal study protocol for the treatment of nasolabial fold wrinkles (lines which run from the sides of the nose to the corners of the mouth). The randomized, double-blind protocol was submitted to the FDA under the agency's Special Protocol Assessment, or SPA. Pursuant to this assessment process, the FDA has agreed that our study design for two identical trials, including subject numbers, clinical endpoints, and statistical analyses, is adequate to provide the necessary data that, depending on the outcome, could form the basis of an efficacy claim for a marketing application. The pivotal Phase III trials evaluated the efficacy and safety of our Fibrocell therapy (USAN name azficel-T) against placebo in approximately 400 subjects total with approximately 200 subjects enrolled in each trial. The injections were completed in January 2008 and the trial data results were disclosed in October 2008. The Phase III trial data results indicated statistically significant efficacy results for the treatment of nasolabial fold wrinkles. The Phase III data analysis, including safety results, was disclosed in October 2008. We submitted the

## **Table of Contents**

related BLA to the FDA in March 2009. In May 2009, the FDA accepted our BLA submission for filing. On October 9, 2009, the FDA's Cellular, Tissue and Gene Therapies Advisory Committee reviewed azficel-T. The committee voted 11 yes to 3 no that the data presented on azficel-T demonstrated efficacy, and 6 yes to 8 no that the data demonstrated safety, both for the proposed indication. The Committee's recommendations are not binding on the FDA, but the FDA will consider their recommendations during their review of our application. On December 21, 2009, Fibrocell Science received a Complete Response letter from the FDA related to the BLA for azficel-T. A Complete Response letter is issued by the FDA's Center for Biologics Evaluation and Research (CBER) when the review of a file is completed and additional data are needed prior to approval. The Complete Response letter requested that Fibrocell Science provide data from a histopathological study on biopsied tissue samples from patients following injection of azficel-T. The histology study (IT-H-001) will evaluate tissue treated with azficel-T as compared to tissue treated with sterile saline (placebo). The study will also provide information about the skin after treatment, including evaluation of collagen and elastin fibrils, and cellular structure of the sampled tissues. The Company submitted a proposed protocol concerning a histopathological study on biopsied samples to the FDA and to the Company's Investigational Review Board (IRB). The IRB has approved the protocol and the Company received the comments from the FDA on the protocol in May 2010. The Company submitted a proposed protocol concerning a histopathological study on biopsied samples to the FDA and to the Company's Investigational Review Board (IRB). The IRB has approved the protocol and the Company received the comments from the FDA on the protocol in May 2010.

On May 13, 2010, the Company announced the initiation of a small histology study (IT-H-001) of azficel-T, an autologous cell therapy currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe nasolabial fold wrinkles. The study has a target enrollment of approximately 20 participants from the completed and statistically significant pivotal Phase III studies of azficel-T (IT-R-005 and IT-R-006). The Company announced on July 8, 2010, the completion of enrollment of and first treatment visits for participants in its histology study of azficel-T. The second treatment visits for participants enrolled in the histology study of azficel-T were completed by the end of July.

The Complete Response letter also requested finalized Chemistry, Manufacturing and Controls (CMC) information regarding the manufacture of azficel-T as follow-up to discussions that occurred during the BLA review period, as well as revised policies and procedures regarding shipping practices, and proposed labeling. The Company is currently working on obtaining the finalized CMC information for the FDA as well as the revised policies and procedures regarding shipping practices and the proposed labeling.

The United States Adopted Names (USAN) Council adopted the USAN name, azficel-T, on October 28, 2009, and the FDA is currently evaluating a proposed brand name, Laviv.

**Full Face Rejuvenation Phase II Trial:** In March 2007, the Predecessor Company commenced an open label (unblinded) trial of approximately 50 subjects. Injections of azficel-T began to be administered in July 2007. This trial was designed to further evaluate the safety and use of azficel-T to treat fine lines and wrinkles for the full face. Five investigators across the United States participated in this trial. The subjects received two series of injections approximately one month apart. In late December 2007, all 45 remaining subjects completed injections. The subjects were followed for twelve months following each subject's last injection. Data results related to this trial were disclosed in August 2008, which included top line positive efficacy results related to this open label Phase II trial. Additional safety data from this trial, collected through telephone calls placed to participating subjects twelve months from the date of their final study treatment, were submitted to the FDA on November 1, 2009. No changes to the safety profile of azficel-T were identified during our review of this data.

### **Therapeutic Development Programs**

**Acne Scars Phase II/III Trial:** In November 2007, the Predecessor Company commenced an acne scar Phase II/III study. This study included approximately 95 subjects. This placebo controlled trial was designed to evaluate the use of azficel-T to correct or improve the appearance of acne scars. Each subject served as their own control, receiving azficel-T on one side of their face and placebo on the other. The subjects received three treatments two weeks apart. The follow-up and evaluation period was completed four months after each subject's last injection. In March 2009, the Predecessor Company disclosed certain trial data results, which included statistically significant efficacy results for

the treatment of moderate to severe acne scars. Compilation of safety data and data related to the validation of the study photo guide assessment scale discussed below is ongoing and is also subject to additional financing.

**Table of Contents**

In connection with this acne scar program, the Predecessor Company developed a photo guide for use in the evaluator assessment of acne study subjects. The Predecessor Company had originally designed the acne scar clinical program as two randomized, double-blind, Phase III, placebo-controlled trials. However, our evaluator assessment scale and photo guide have not previously been utilized in a clinical trial. In November 2007, the FDA recommended that the Predecessor Company consider conducting a Phase II study in order to address certain study issues, including additional validation related to our evaluator assessment scale. As such, the Predecessor Company modified our clinical plans to initiate a single Phase II/III trial. This Phase II/III study, was powered to demonstrate efficacy, and has allowed for a closer assessment of the evaluator assessment scale and photo guide that is ongoing. The Successor Company submitted on August 9, 2010, a clinical study report for its Phase II/III study of azficel-T for the treatment of moderate to severe acne scars to the FDA. The next step is to initiate a discussion with the FDA concerning the validation of the evaluator assessment scale and agree the path forward. These steps will be subject to obtaining sufficient financial resources.

**Restrictive Burn Scars Phase II Trial:** In January 2007, the Predecessor Company met with the FDA to discuss our clinical program for the use of azficel-T for restrictive burn scar patients. This Phase II trial would evaluate the use of azficel-T to improve range of motion, function and flexibility, among other parameters, in existing restrictive burn scars in approximately 20 patients. However, the Predecessor Company delayed the screening and enrollment in this trial until such time as we raise sufficient additional financing and gather additional data regarding the burn scar market.

**Dental Study Phase II Trial:** In late 2003, the Predecessor Company completed a Phase I clinical trial for the treatment of condition relating to periodontal disease, specifically to treat Interdental Papillary Insufficiency. In the second quarter of 2005, the Predecessor Company concluded the Phase II dental clinical trial with the use of azficel-T and subsequently announced that investigator and subject visual analog scale assessments demonstrated that the azficel-T was statistically superior to placebo at four months after treatment. Although results of the investigator and subject assessment demonstrated that the azficel-T was statistically superior to placebo, an analysis of objective linear measurements did not yield statistically significant results.

In 2006, the Predecessor Company commenced a Phase II open-label dental trial for the treatment of Interdental Papillary Insufficiency. This single site study included 11 subjects. All study treatment and follow up visits were completed, but full analysis of the study was previously placed on internal hold due to our financial resource constraints. The Company is also currently reviewing potential other clinical paths in the dental arena.

**Agera Skincare Systems**

The Successor Company markets and sells a skin care product line through our majority-owned subsidiary, Agera Laboratories, Inc., which the Predecessor Company acquired in August 2006. Agera offers a complete line of skincare systems based on a wide array of proprietary formulations, trademarks and nano-peptide technology. These skincare products can be packaged to offer anti-aging, anti-pigmentary and acne treatment systems. Agera primarily markets its products in both the United States and Europe (primarily the United Kingdom).

**Critical Accounting Policies**

The following discussion and analysis of financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in conformity with accounting principles generally accepted in the United States of America. However, certain accounting policies and estimates are particularly important to the understanding of our financial position and results of operations and require the application of significant judgment by our management or can be materially affected by changes from period to period in economic factors or conditions that are outside of the control of management. As a result, they are subject to an inherent degree of uncertainty. In applying these policies, our management uses their judgment to determine the appropriate assumptions to be used in the determination of certain estimates. Those estimates are based on our historical operations, our future business plans and projected financial results, the terms of existing contracts, our observance of trends in the industry, information provided by our customers and information available from other outside sources, as appropriate. The following discusses our critical accounting policies and estimates.



## **Table of Contents**

**Warrant Liability:** The warrants for the Successor Company are measured at fair value and liability-classified under ASC 815, Derivatives and Hedging, ( ASC 815 ) because the warrants contain down-round protection and therefore, do not meet the scope exception for treatment as a derivative under ASC 815. Since down-round protection is not an input into the calculation of the fair value of the warrants, the warrants cannot be considered indexed to the Company's own stock which is a requirement for the scope exception as outlined under ASC 815. The fair value of the warrants is determined using the Black-Scholes option pricing model and is affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. We will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability.

**Stock-Based Compensation:** We account for stock-based awards to employees and non-employees using the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. We use a Black-Scholes options-pricing model to determine the fair value of each option grant as of the date of grant for expense incurred. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. Expected volatility is based on historical volatility of our competitor's stock since the Predecessor Company ceased trading as part of the bankruptcy and emerged as a new entity. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected lives for options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted. We estimate future forfeitures of options based upon expected forfeiture rates.

**Research and Development Expenses:** Research and development costs are expensed as incurred and include salaries and benefits, costs paid to third-party contractors to perform research, conduct clinical trials, develop and manufacture drug materials and delivery devices, and a portion of facilities cost. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. Invoicing from third-party contractors for services performed can lag several months. We accrue the costs of services rendered in connection with third-party contractor activities based on our estimate of management fees, site management and monitoring costs and data management costs. Actual clinical trial costs may differ from estimated clinical trial costs and are adjusted for in the period in which they become known.

### **Recently Issued Accounting Pronouncements**

In October 2009, the FASB issued ASU No. 2009-13, Multiple-Deliverable Revenue Arrangements, or ASU 2009-13. ASU 2009-13, amends existing revenue recognition accounting pronouncements that are currently within the scope of FASB ASC Topic 605. This consensus provides accounting principles and application guidance on how the arrangement should be separated, and the consideration allocated. This guidance changes how to determine the fair value of undelivered products and services for separate revenue recognition. Allocation of consideration is now based on management's estimate of the selling price for an undelivered item where there is no other means to determine the fair value of that undelivered item. This new approach is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. We are currently evaluating the guidance to determine the impact on the Company's results of operations, cash flows, and financial position.

In March 2010, the FASB ratified ASU 2010-17, *Milestone Method of Revenue Recognition*, that the milestone method is a valid application of the proportional performance model for revenue recognition if the milestones are substantive and there is substantive uncertainty about whether the milestones will be achieved. The Task Force agreed that whether a milestone is substantive is a judgment that should be made at the inception of the arrangement. To meet the definition of a substantive milestone, the consideration earned by achieving the milestone (1) would have to be commensurate with either the level of effort required to achieve the milestone or the enhancement in the value of the item delivered, (2) would have to relate solely to past performance, and (3) should be reasonable relative to all deliverables and payment terms in the arrangement. No bifurcation of an individual milestone is allowed and there can be more than one milestone in an arrangement. The new guidance will be effective for interim and annual periods beginning on or after June 15, 2010. We are currently evaluating the guidance to determine the impact on the Company's results of operations, cash flows, and financial position.



## **Table of Contents**

### **Emergence from Voluntary Reorganization Under Chapter 11 Proceedings and Reorganization Plan**

Fibrocell emerged from Chapter 11 on September 3, 2009. See Note 1 in the accompanying Consolidated Financial Statements.

### **Basis of Presentation**

As of September 1, 2009, the Successor Company adopted fresh-start accounting in accordance with ASC 852-10, Reorganizations. The Successor Company selected September 1, 2009, as the date to effectively apply fresh-start accounting based on the absence of any material contingencies at the August 27, 2009 confirmation hearing and the immaterial impact of transactions between August 27, 2009 and September 1, 2009. The adoption of fresh-start accounting resulted in the Successor Company becoming a new entity for financial reporting purposes.

Accordingly, the financial statements prior to September 1, 2009 are not comparable with the financial statements for periods on or after September 1, 2009. References to Successor or Successor Company refer to the Company on or after September 1, 2009, after giving effect to the cancellation of Isolagen, Inc. common stock issued prior to the Effective Date, the issuance of new Fibrocell Science, Inc. common stock in accordance with the Plan, and the application of fresh-start accounting. References to Predecessor or Predecessor Company refer to the Company prior to September 1, 2009. See Note 5 Fresh Start Accounting in the notes to these Consolidated Financial Statements for further details.

For discussions on the results of operations, the Successor Company has compared the results of operations for the three and six months ended June 30, 2010, with the results of operations for the three and six months ended June 30, 2009. The Successor Company believes that the comparison of the financial results provide management and investors a more meaningful analysis of the Company's performance and trends.

The following discussion should be read in conjunction with the Consolidated Financial Statements and the accompanying Notes to the Consolidated Financial Statements in Part 1, Item 1 of this report.

### **Results of Operations Comparison of the three months ended June 30, 2010 and 2009**

**REVENUES.** Revenue remained relatively constant at \$0.3 million for the three months ended June 30, 2010 and 2009. Our revenue from continuing operations is from the operations of Agera, which we acquired on August 10, 2006. Agera markets and sells a complete line of advanced skin care systems based on a wide array of proprietary formulations, trademarks and non-peptide technology. For the three months ended June 30, 2010 and 2009, 75% and 66%, respectively, of Agera's revenue were to one foreign customer. As such, total revenue is subject to fluctuation depending primarily on the orders received and orders fulfilled with respect to this large customer.

**COST OF SALES.** Cost of sales increased approximately \$0.1 million to \$0.2 million for the three months ended June 30, 2010 as compared to \$0.1 million for the three months ended June 30, 2009. Our cost of sales relates to the operation of Agera. As a percentage of revenue, Agera cost of sales were approximately 67% for the three months ended June 30, 2010 and 43% for the three months ended June 30, 2009. Cost of sales as a percentage of revenue has increased primarily due to increased costs of components.

**SELLING, GENERAL AND ADMINISTRATIVE EXPENSES.** Selling, general and administrative expenses increased by approximately \$0.7 million, or 70%, to \$1.8 million for the three months ended June 30, 2010 as compared to \$1.1 million for the three months ended June 30, 2009. The increase primarily relates to a \$0.4 million increase in payroll related expenses and \$0.3 million increase related to consultants for financing and marketing, office expenses and promotion expense.

## **Table of Contents**

**RESEARCH AND DEVELOPMENT.** Research and development expenses increased by approximately \$1.0 million, or 204%, to \$1.5 million for the three months ended June 30, 2010 as compared to \$0.5 for the three months ended June 30, 2009. The increase primarily relates to a \$0.2 million increase in payroll related expenses, \$0.6 million increase in consulting fees and a \$0.2 million increase in laboratory costs associated with clinical and manufacturing activities in our Exton, Pennsylvania location. Research and development costs are composed primarily of costs related to our efforts to gain FDA approval for our Fibrocell Therapy for specific dermal applications in the United States, as well as costs related to other potential indications for our Fibrocell Therapy, such as acne scars and burn scars. Also, research and development expense includes costs to develop manufacturing, cell collection and logistical process improvements. Research and development costs primarily include personnel and laboratory costs related to these FDA trials and certain consulting costs. The total inception (December 28, 1995) to date cost of research and development as of August 31, 2009 for the Predecessor Company was \$56.3 million and total inception (September 1, 2009) to date cost of research and development as of June 30, 2010, for the Successor Company was \$4.5 million. The FDA approval process is extremely complicated and is dependent upon our study protocols and the results of our studies. In the event that the FDA requires additional studies for our product candidate or requires changes in our study protocols or in the event that the results of the studies are not consistent with our expectations, the process will be more expensive and time consuming. Due to the complexities of the FDA approval process, we are unable to predict what the cost of obtaining approval for our dermal product candidate will be.

**LOSS FROM DISCONTINUED OPERATIONS.** Discontinued operations had a loss of less than \$0.1 million for the three months ended June 30, 2010 as compared to a loss of \$0.1 million for the three months ended June 30, 2009. Administrative costs related primarily to the Swiss operations comprised approximately less than \$0.1 million during the three months ended June 30, 2010 and \$0.1 million for the three months ended June 30, 2009.

**REORGANIZATION ITEMS, NET.** On June 15, 2009, Isolagen, Inc. and its wholly-owned, U.S. subsidiary Isolagen Technologies, Inc., filed voluntary petitions for relief under Chapter 11 of the federal bankruptcy laws in the United States Bankruptcy Court for the District of Delaware, as more fully discussed under Note 1 in the accompanying Consolidated Financial Statements. There were no reorganization costs for the three months ended June 30, 2010 as compared to reorganization costs of \$0.6 million recorded for the three months ended June 30, 2009, which were comprised primarily of legal fees and the unamortized debt acquisition costs, as of the date of the bankruptcy filing, related to the pre-petition 3.5% Convertible Subordinated Notes.

**INTEREST EXPENSE.** Interest expense decreased \$0.8 million to \$0.2 million for the three months ended June 30, 2010, as compared to \$1.0 million for the three months ended June 30, 2009. Our 2010 interest expense is related to our \$6.0 million (in original principal amount) 12.5% notes. Our 2009 interest expense is related to our 3.5% convertible subordinated notes, of which \$79.2 million was outstanding at June 30, 2009, as well as the related amortization of deferred debt issuance costs of \$0.4 million, for the three months ended June 30, 2009. With the emergence out of bankruptcy, the 3.5% convertible subordinated notes were exchanged for \$6.0 million of debt and 3,960,000 shares of the new common stock.

**NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS.** Net loss attributable to common shareholders decreased approximately \$1.4 million to a net loss of \$1.7 million for the three months ended June 30, 2010, as compared to a net loss of \$3.1 million for the three months ended June 30, 2009. This decrease in loss primarily represents the recording of the revaluation of the warrant liability for the preferred stock issued in October 2009 and the warrant liability attached to the common shares issued in March 2010.

### **Results of Operations Comparison of the six months ended June 30, 2010 and 2009**

**REVENUES.** Revenue increased approximately \$0.1 million for the six months ended June 30, 2010 to \$0.5 million as compared to \$0.4 million for the six months ended June 30, 2009. Our revenue from continuing operations is from the operations of Agera which we acquired on August 10, 2006. Agera markets and sells a complete line of advanced skin care systems based on a wide array of proprietary formulations, trademarks and non-peptide technology. For the six months ended June 30, 2010 and 2009, 72% and 55%, respectively, of Agera's revenue were to one foreign customer. As such, total revenue is subject to fluctuation depending primarily on the orders received and orders fulfilled with respect to this large customer. Due to our financial statement presentation of our United Kingdom operation as a discontinued operation, our revenue for all periods presented is representative of only Agera, as all

historical United Kingdom revenue is reflected in loss from discontinued operations.

## **Table of Contents**

**COST OF SALES.** Cost of sales increased approximately \$0.1 million to \$0.3 million for the six months ended June 30, 2010 as compared to \$0.2 million for the six months ended June 30, 2009. Our cost of sales relates to the operation of Agera. As a percentage of revenue, Agera cost of sales were approximately 58% and 42% for the six months ended June 30, 2010 and 2009, respectively. Cost of sales as a percentage of revenue has increased primarily due to the impact of a physical inventory adjustment in the first quarter of 2010 and increased costs of components.

**SELLING, GENERAL AND ADMINISTRATIVE EXPENSES.** Selling, general and administrative expenses increased by approximately \$1.5 million, or 69%, to \$3.8 million for the six months ended June 30, 2010 as compared to \$2.3 million for the six months ended June 30, 2009. The increase primarily relates to a \$0.7 million increase in payroll related expenses, \$0.5 million increase related to general and administrative expenses associated with consultants for financing and marketing as well as office expenses and \$0.3 million increase related to legal expenses. Legal expenses for the six months ended June 30, 2009 were (\$0.1) million due to a \$0.3 million reimbursement received from our insurance carrier related to defense costs associated with our class action and derivative matters. Had we not received this reimbursement, legal expenses for the six months ended June 30, 2010 and June 30, 2009 would have been consistent at \$0.2 million.

**RESEARCH AND DEVELOPMENT.** Research and development expenses increased by approximately \$1.2 million, or 79%, to \$2.7 million for the six months ended June 30, 2010 as compared to \$1.5 for the six months ended June 30, 2009. The increase primarily relates to a \$0.3 million increase in payroll related expenses, \$0.6 million increase in consulting fees and \$0.3 million increase in laboratory costs associated with clinical and manufacturing activities in our Exton, Pennsylvania location. Research and development costs are composed primarily of costs related to our efforts to gain FDA approval for our Fibrocell Therapy for specific dermal applications in the United States, as well as costs related to other potential indications for our Fibrocell Therapy, such as acne scars and burn scars. Also, research and development expense includes costs to develop manufacturing, cell collection and logistical process improvements. Research and development costs primarily include personnel and laboratory costs related to these FDA trials and certain consulting costs. The total inception (December 28, 1995) to date cost of research and development as of August 31, 2009 for the Predecessor Company was \$56.3 million and total inception (September 1, 2009) to date cost of research and development as of June 30, 2010, for the Successor Company was \$4.5 million.

The FDA approval process is extremely complicated and is dependent upon our study protocols and the results of our studies. In the event that the FDA requires additional studies for our product candidate or requires changes in our study protocols or in the event that the results of the studies are not consistent with our expectations, the process will be more expensive and time consuming. Due to the complexities of the FDA approval process, we are unable to predict what the cost of obtaining approval for our dermal product candidate will be.

**LOSS FROM DISCONTINUED OPERATIONS.** Discontinued operations had a loss of less than \$0.1 million and \$0.2 million for the six months ended June 30, 2010 and 2009, respectively. Administrative costs related primarily to the Swiss operations comprised approximately less than \$0.1 million and \$0.2 million during the six months ended June 30, 2010 and 2009, respectively.

**REORGANIZATION ITEMS, NET.** On June 15, 2009, Isolagen, Inc. and its wholly-owned, U.S. subsidiary Isolagen Technologies, Inc., filed voluntary petitions for relief under Chapter 11 of the federal bankruptcy laws in the United States Bankruptcy Court for the District of Delaware, as more fully discussed under Note 1 in the accompanying Consolidated Financial Statements. A reorganization gain, net of reorganization costs, of less than \$0.1 million was recorded for the six months ended June 30, 2010, which was comprised primarily of administrative costs offset by the gain of discharge of liabilities. Reorganization costs of \$0.6 million were recorded for the six months ended June 30, 2009, which were comprised primarily of legal fees and the unamortized debt acquisition costs, as of the date of the bankruptcy filing, related to the pre-petition 3.5% Convertible Subordinated Notes.

**INTEREST EXPENSE.** Interest expense decreased \$1.5 million to \$0.4 million for the six months ended June 30, 2010, as compared to \$1.9 million for the six months ended June 30, 2009. Our 2010 interest expense is related to our \$6.0 million (in original principal amount) 12.5% notes. Our 2009 interest expense is related to our 3.5% convertible subordinated notes, of which \$79.2 million was outstanding at June 30, 2009, as well as the related amortization of deferred debt issuance costs of \$0.6 million, for the six months ended June 30, 2009. With the emergence out of bankruptcy, the 3.5% convertible subordinated notes were exchanged for \$6.0 million of debt and 3,960,000 shares of

the new common stock.

**Table of Contents**

**NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS.** Net loss attributable to common shareholders increased approximately \$0.2 million to a net loss of \$6.4 million for the six months ended June 30, 2010, as compared to a net loss of \$6.2 million for the six months ended June 30, 2009.

**Liquidity and Capital Resources****Cash Flows**

Net cash provided by (used in) operating, investing and financing activities for the six months ended June 30, 2010 and 2009, respectively, were as follows:

	<b>Six Months Ended June 30,</b>	
	<b>2010</b>	<b>2009</b>
	<b>(in millions)</b>	
Cash flows from operating activities	\$ (4.4)	\$ (3.1)
Cash flows from investing activities		
Cash flows from financing activities	3.3	1.3

**OPERATING ACTIVITIES.** Cash used in operating activities during the six months ended June 30, 2010 amounted to \$4.4 million, an increase of \$1.3 million over the six months ended June 30, 2009. The increase in our cash used in operating activities over the prior year is primarily due to an increase in net losses (adjusted for non-cash items) of \$1.0 million, in addition to a decrease of \$0.3 million of operating cash inflows from changes in operating assets and liabilities.

Our negative operating cash flows for the six months ended June 30, 2010 were funded from cash on hand at December 31, 2009, which were primarily the result of previously completed debt and equity offerings as well as funds received from the secured bridge loan, DIP financing, exit financing and the funds received for the issuance of preferred stock in 2009. Funds were also received from the proceeds of the issuance of common stock in March 2010, discussed further below.

**INVESTING ACTIVITIES.** Less than \$0.1 million cash was provided by or used for investing activities during the six months ended June 30, 2010 and the six months ended June 30, 2009.

**FINANCING ACTIVITIES.** There was \$3.3 million, net of fees, cash proceeds from financing activities during the six months ended June 30, 2010, as compared to cash received of \$1.3 million from financing activities during the six months ended June 30, 2009. In March 2010, we sold to investors in the aggregate 5,076,664 shares of Company common stock at a purchase price of \$0.75 per share. Each purchaser also received a warrant to purchase the same number of shares of common stock acquired in the offering at an exercise price of \$0.98 per share.

**Working Capital**

As of June 30, 2010, we had cash and cash equivalents of approximately \$0.3 million and negative working capital of \$1.3 million. As discussed in the above paragraph, in early March 2010, we raised approximately \$3.4 million, net of fees as a result of the issuance of common stock and warrants.

In early July 2010, the Successor Company raised approximately \$2.7 million less fees as a result of the issuance of preferred stock and warrants. We believe that our existing capital resources are adequate to sustain our operation through approximately mid-September 2010. As such, we will require additional cash resources prior to or during approximately mid- September 2010, or we will likely cease operations. Even if we are able to obtain financing prior to mid- September 2010, we will need to access the capital markets in the future in order to continue to fund future operations. There is no guarantee that any such required financing will be available on terms satisfactory to us or available at all. These matters create uncertainty relating to our ability to continue as a going concern. The accompanying consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or liabilities that might result from the outcome of these uncertainties.

**Table of Contents**

***Factors Affecting Our Capital Resources***

Inflation did not have a significant impact on the Company's results during the six months ended June 30, 2010.

***Off-Balance Sheet Transactions***

We do not engage in material off-balance sheet transactions.

**ITEM 3. Quantitative and Qualitative Disclosures About Market Risk**

Market risk is the potential loss arising from adverse changes in market rates and prices, such as foreign currency exchange rates or interest rates.

***Foreign Exchange Rate Risk***

We do not believe that we have significant foreign exchange rate risk at June 30, 2010.

We do not enter into derivatives or other financial instruments for trading or speculative purposes.

**ITEM 4. CONTROLS AND PROCEDURES**

- (a) Disclosure Controls and Procedures. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (the Certifying Officers), have evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of the end of the period covered by this report. Based on that evaluation, the Certifying Officers have concluded that our disclosure controls and procedures were effective for the purpose of ensuring that material information required to be in this quarterly report is made known to them by others on a timely basis and that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.
- (b) Changes in Internal Controls. There has been no change in our internal control over financial reporting that occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**Table of Contents**

**PART II OTHER INFORMATION**

**ITEM 1A. RISK FACTORS**

There have been no material changes to the Risk Factors disclosed in our December 31, 2009 Form 10-K. Investors should consider the risks and uncertainties set forth in our December 31, 2009 Form 10-K, or updates to such risks and uncertainties, prior to making an investment decision with respect to our securities.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

None.

**ITEM 6. EXHIBITS**

**(a) Exhibits**

**EXHIBIT NO. IDENTIFICATION OF EXHIBIT**

31.1	Certification pursuant to Rule 13a-14(a) and 15d-14(a), required under Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification pursuant to Rule 13a-14(a) and 15d-14(a), required under Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

**SIGNATURES**

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Fibrocell Science, Inc.

By: /s/ Declan Daly

Declan Daly  
Chief Financial Officer

Date: August 13, 2010